

# CURRICULUM VITAE

Janet A. Englund, M.D.

## PERSONAL DATA:

Birthplace: Born: -----(b)(6)-----  
Citizenship: (b)(6)  
Status: -----(b)(6)-----

## ***Business Address:***

*Seattle Children's Hospital*  
*Division of Infectious Diseases, Seattle Children's Hospital*  
*4800 Sand Point Way N.E., R5441*  
*Seattle, WA 98105*  
*Telephone: 206-987-2239 or 206-987-6487; pager 206-469-1409*  
*e-mail: [janet.englund@seattlechildrens.org](mailto:janet.englund@seattlechildrens.org)*

## EDUCATION:

M.D.	1980	University of Michigan Medical School, Ann Arbor, MI
B.S.	(b)(6)	Microbiology, w/Distinction and High Honors, University of Michigan, Ann Arbor, MI
Abitur	(b)(6)	Mathematics, Max Planck Gymnasium, Delmenhorst, Republic of West Germany

## POSTGRADUATE TRAINING:

1984 - 1987	Fellow in Pediatric Infectious Diseases, Department of Pediatrics, University of Minnesota Medical School Minneapolis, MN; September 1984 to September 1987
1984	Pediatrician at Hospital Samuteb, Kapanga, Zaire. Worked in pediatric ward, leprosarium, TB ward. February 1984 to July 1984
1983 - 1983	Clinical Postdoctoral Fellow in Virology, Department of Laboratory Medicine, University of Minnesota. Minneapolis, MN; July 1983 to December 1983
1980 - 1983	Pediatric Residency, University of Minnesota Medical School, June 1980 to July 1983

## FACULTY/ACADEMIC POSITIONS HELD:

2008-	Professor, Department of Pediatrics, Division of Pediatric Infectious Diseases, University of Washington, Seattle Children's Hospital, Seattle, WA
2003 -	Clinical Associate, Seattle Cancer Care Alliance, Seattle, WA
2002 - 2008	Associate Professor, Division of Pediatric Infectious Diseases, Immunology, and Rheumatology, University of Washington, Children's Hospital & Regional Medical Center
2002 -	Affiliate Investigator, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
1998 - 2002	Associate Professor, Department of Pediatrics, University of Chicago, Chicago, IL
1995 - 1998	Associate Professor with Tenure, Department of Microbiology and Immunology, and Pediatrics, Baylor College of Medicine, Houston, TX
1988 - 1995	Assistant Professor, Department of Microbiology and Immunology, and Pediatrics, Baylor College of Medicine, Houston, TX
1987 - 1988	Clinical Postdoctoral Research Associate, AIDS Treatment Evaluation Unit, Clinical Virology Laboratory, University of Minnesota, Minneapolis, MN
1984 - 1984	Pediatrician at Hospital Samuteb, Kapanga, Zaire, February 1984 to July 1984

#### **HOSPITAL POSITIONS HELD:**

2002 - present	University of Washington School of Medicine, Seattle, WA
2002 - present	Attending Pediatrician, Seattle Children's Hospital, Seattle, WA
1998 - 2002	Attending Pediatrician, University of Chicago Children's Hospital, Chicago, IL
1988 - 1998	Attending Pediatrician, Newborn Nursery, Texas Women's Hospital, Houston, TX
1988 - 1998	Attending Physician, Texas Children's Hospital, Houston, TX
1988 - 1998	Attending Pediatrician, Ben Taub General Hospital, Harris County Hospital District, Houston, TX

#### **HONORS and AWARDS:**

2005	US FDA Advisory Committee Service Award, 2005
2008	Golden Stethoscope Award, Seattle Magazine

#### **BOARD CERTIFICATION:**

1985	Diplomate, Board Certified, American Board of Pediatrics
1994	Board Certified, Pediatric Infectious Diseases
2001	Diplomate, Board Recertified, American Board of Pediatrics
2001	Recertified, Pediatric Infectious Diseases
2009	Recertified, Pediatric Infectious Diseases

#### **CURRENT LICENSES TO PRACTICE:**

------(b)(6)-----	2002-present	Active	State of Washington Medical License
------(b)(6)-----	1998-2004	Inactive	State of Illinois Medical License

#### **PROFESSIONAL ORGANIZATIONS:**

American Academy of Pediatrics  
American Society for Microbiology  
American Society for Transplantation  
Infectious Disease Society of America, Fellow (1997)  
Pediatric Infectious Diseases Society  
Society for Pediatric Research  
International Society for Infections in the Immunocompromised Host

#### **TEACHING RESPONSIBILITIES:**

*Clinical Supervisor;* Pediatric Infectious Diseases Fellows; Two months annually. In addition, one to two medical residents and medical students also supervised during this time. Responsibilities included patient care, infectious diseases teaching, and outpatient clinic and general supervision. Assist with clinical case presentations, lectures, and morning report.

*Lecturer 2002-20013:* Clinical Epidemiology/Public Health Course 520 at University of Washington since 2003-2008; Clinical Epidemiology- Vaccines at Univ. Washington, Nov 2009-2012; Clinical Disease and Zoonosis- Influenza at Univ. Washington, April 2010-12. Annual lecture in vaccine epidemiology to fellows. Also lectures given annually at international Fondation Merieux/WHO Vaccinology Course, Annecy, France for 2-3 days annually since 1999. Guest lecturer for AAP, King County and Washington State Health Department and Immunization clinics, Immunization Coalition, and nursing and medical meetings throughout the Pacific Northwest annually.

*Advisor:* For ID fellows in Heme-Onc and BMT service (one hour/week); research supervision for 1-2 fellows annually and for 1-2 residents/students/ Public Health students doing research projects

Past experience, 1998-2002:

*Lecture at University of Chicago, Pritzker School of Medicine:* Medical Student Microbiology (4 hours annually); Medical Student HIV Course (4 hours annually); Basic Microbiology -Undergraduate Course (4 hours of basic virology 2000-2002)

*Clinical Supervisor* - Outpatient Pediatric ID Clinic - supervision of nurse practitioners, medical residents, fellows, and students, providing care of children infected with HIV, travel clinic, TB, and referral patients; Inpatient ID service 3 months annually.

## TRAINING

### Post-Doctoral:

- (b)(6)-----: Baylor College of Medicine and MD Anderson Cancer Center, with ---(b)(6)----. Study of impact of respiratory viruses in patients with ALL; Subsequently trained in internal medicine/ Infectious Diseases
- (b)(6)-----: Baylor College of Medicine, Dept. Microbiology; currently Assistant Professor at -----(b)(6)----- . Study of maternal immunization with pneumococcal and RSV vaccines, through VTEU/NIH, currently Assistant Professor of -----(b)(6)-----.
- (b)(6)-----: University of Chicago, Pediatric Infectious Diseases, with ---(b)(6)---; studied antiretroviral resistance in pediatric HIV+ patients. -----(b)(6)-----.
- (b)(6)-----: Univ. Chicago, Pediatric Infectious Disease; Studied vaccine responses in HIV+ pediatric patients. Obtained faculty position at -----(b)(6)----- in Pediatric Infectious Diseases, 2003-2006; currently on staff, -----(b)(6)-----.
- (b)(6)-----: Univ. Washington, Dept. Pediatrics – mentor in fellowship training, supported by grants from PIDS/MedImmune and Joel Meyers Fund. Studying impact of respiratory viruses in immunocompromised stem cell transplant patients. Assistant Professor, -----(b)(6)-----.
- (b)(6)-----: Univ. Washington/Fred Hutchinson Cancer Research Center, in transplant ID fellowship training, Studied impact of RSV antibody in disease progression in HCT recipients. Currently Assistant Professor, -----(b)(6)-----.
- (b)(6)-----: Visiting faculty from -----(b)(6)-----, 2006; supported by University of (b)(6). Studied diagnosis of pertussis in children and adults. Returned to faculty position in the Dept. of Pediatrics, ---(b)(6)---.
- (b)(6)-----: University of Washington/Seattle Children's Hospital: Postdoctoral research with emphasis on respiratory viral co-infections and viral load in young children. Currently Assistant Professor, Pharmacology, -----(b)(6)-----.
- (b)(6)-----: Research on influenza viral shedding and disease in health care workers.
- (b)(6)-----: Fred Hutchinson Cancer Research Center/Seattle Children's Hospital: Postdoctoral research in diagnosis and impact of influenza resistant to antiviral therapy, identification of new human parechoviruses in children attending daycare. Currently Microbiology/Pediatrics faculty at -----(b)(6)-----.
- (b)(6)-----: University of Washington/Seattle Children's Hospital: Postdoctoral medical fellow, section of Internal Medicine/Infectious Disease. Studied RSV molecular epidemiology/ received MPH at Univ. Washington. Currently Instructor, -----(b)(6)-----.
- (b)(6)-----: University of Washington/Seattle Children's Hospital: Postdoctoral Pediatric ID fellow. Studying rhinovirus and parainfluenza virus infections in immunocompromised hosts

### **Doctoral Training:**

- (b)(6) -----, supervisor in PhD program at University of Washington School of Public Health. Completed, June 2009. Studied epidemiology of respiratory viruses and bocavirus in hospital and daycare. Currently Assistant Professor, ----- (b)(6) -----.
- (b)(6) ----- – completed PhD program in Public Health at UNC, 2007. Thesis committee. Pertussis epidemiology and vaccine cost effectiveness (with ---- (b)(6) ----).

### **Resident and Student Research Training**

- (b)(6) -----: Study of immunity after measles vaccine in HIV+ children (started as medical student at U. Chicago, completed as resident at Seattle Children's Hospital and Regional Medical Center)
- (b)(6) ----: Clinical study of bacterial infection in Pediatric ICU patients with RSV; in medical school
- (b)(6) -----: Clinical study of influenza in pediatric cancer patients; currently fellow in pediatric oncology, UCSF.
- (b)(6) ----: Clinical studies of coronavirus in otherwise healthy and immunocompromised patients; Pediatric residency at CHOP; entering fellowship in neonatology
- (b)(6) -----: Clinical review of virologic causes of bronchiolitis. Medical Student, Univ. Virginia
- (b)(6) -----: Diagnosis of human parechovirus infections in daycare. Premedical, MPH student
- (b)(6) -----: Clinical research; Review of invasive fungal disease in immunocompromised patients. Pre-MPH student

### **EDITORIAL RESPONSIBILITIES:**

1998 - present Editorial Board and reviewer, *Antiviral Therapy*

Ad hoc Reviewer – *Acta Paediatrica*, *Annals of Internal Medicine*, *Antimicrobial Agents & Chemotherapy*, *Antiviral Therapy*, *Archives Adolescent Medicine*, *Biology Blood and Marrow Transplantation*, *Blood*, *Bone Marrow Transplantation*, *Clinical Infectious Diseases*, *Diagnostic Microbiology Infectious Disease*, *Emerging Infectious Diseases*, *JAMA*, *Journal of Clinical Microbiology*, *Journal of Clinical Virology*, *Journal of Cystic Fibrosis*, *Journal of Infectious Diseases*, *Journal of Medical Virology*, *Journal of Pediatrics*, *Lancet*, *Lancet ID*, *Mayo Clinic Proceedings*, *Pediatrics*, *Pediatric Infectious Disease Journal*, *Vaccine*  
Co-Founder, *Journal of the Pediatric Infectious Diseases Society* – initiated, March 2012

### **SPECIAL NATIONAL/INTERNATIONAL RESPONSIBILITIES:**

- *Member*, Advisory Group for Vaccine Safety for Pregnant Women, World Health Organization, 2012-13
- *Member*, Strategic Advisory Group of Experts (SAGE) on Influenza Working Group, World Health Organization, 2010-13
- *Ad hoc Member*, Evaluation of Influenza Pandemic Impact and Severity, CDC, Atlanta, GA Aug. 25, 2010
- *Member*, Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control. Member of influenza and respiratory syncytial virus prophylaxis working groups, 2007-present
- *Chair*, HPV working group of ACIP, Centers for Disease Control, 2007-2011
- *President*, Pediatric Infectious Disease Society, 2011-13
- *Reviewer and Consultant*, Bill and Melinda Gates Fndn, Maternal and Pediatric Vaccines, Oct. 2008-present
- *Secretary-Treasurer*, Pediatric Infectious Disease Society, 2007-2009
- *Member* and PIDS representative, IDSA Expert Panel on Seasonal Influenza in Adults and Children, 2006-present
- *Member and Reviewer*, Thrasher Foundation, 2004-2010
- *Member*, American Board of Pediatrics, Subboard of Pediatric Infectious Diseases, 2005-10
- *Adjunct member*, Pandemic Influenza Preparedness/Antiviral SubCommittee- HHS/CDC, Summer 2005
- *Member*, Data Safety Monitoring Board for CDC-sponsored "Intradermal Influenza Vaccine Study in Children, Dominican Republic, 2006-present

- *Committee member*, Antiviral Drugs for Pandemic Influenza, National Vaccine Program Office, Atlanta, Georgia, July 14, 2003 - present.
- *Council member*, Pediatric Infectious Disease Society, 2003-2007.
- Advisory Board, FDA review, Center for Biologics Evaluation and Research, Laboratory of Pediatric and Respiratory Viral Diseases, June 2006.
- *Member*, Food and Drug Administration (FDA) Antiviral Advisory Committee (AVAC), September, 2001-October, 2005. Review of antiviral, antifungal, and immunomodulatory anti-infectives; *Chairman*, FDA-AVAC, January 2004-October 2005
- *Committee member*, Pandemic Flu Preparedness: National Vaccine Advisory Committee- NVAC; 2005
- *Adjunct member*, Global Advisory Committee on Vaccine Safety, World Health Organization, Dec. 2003.
- *Committee member*, Antiviral Drugs for Pandemic Influenza, National Vaccine Program Office, Atlanta, GA, July 14, 2003.
- *Member*, Food and Drug Administration (FDA) Pediatric Anti-Infective Drugs Subcommittee, 2003 Advisory Meeting: Development of Antiretroviral Drugs in HIV-exposed and infected neonates – March 3, 2003, Rockville, MD.
- *Acting Chair*, FDA Antiviral Advisory Committee – Immunosuppressive agents, - January 23-24, 2002.
- *Committee Member*, Data Safety and Monitoring Board, Acellular Pertussis Vaccines in Adolescents and Adults, sponsored by ----(b)(4)----, 2000-2002.
- *Committee Member*, ad hoc "Working Group on Antiretroviral Therapy of HIV-infected Children," 1997 – 2002.
- *Ad hoc member*, Consensus statement on antiretroviral therapy –published in Federal Register (Aug. 1997, Jan. 2000, Oct. 2001).
- *Committee Member*, Centers for Disease Control Advisory Panel. Pandemic Preparedness: Antiviral Agents for Pandemic Influenza, CDC, Atlanta, GA. March 6-7, 2001.
- *Committee Member*, Data Safety and Monitoring Board, Trivalent live attenuated influenza virus vaccine in HIV-infected children (NIAID-sponsored) 1999-2000.
- *Committee Member*, FDA Review panel of CBER/Viral and Respiratory Division, 1997.
- *Committee Member*, Pediatric AIDS Core Protocol for the Evaluation of Antiretroviral Drugs (PACTG) 1993-1996.

#### **SPECIAL LOCAL RESPONSIBILITIES:**

Director, Pediatric Transplant Infectious Diseases –Children’s Hospital/UW/FHCRC (2006-present)

Co-Chair, Pharmacy and Therapeutics Committee, Children’s Hospital and Regional Medical Center, 2004-2009

Member, Faculty Recognition Committee, Children’s Hospital, 2007-present

Member, Clinical Research Committee, Children’s Hospital, 2005-2007; chair of CCTR Pediatric Pilot Grants, and member of Mentored Scholar Committee

Appointed member, Vaccine Advisory Committee, Dept. of Health, State of Washington, Oct, 2004.

Liaison of BMT team, Seattle Cancer Care Alliance/Fred Hutchinson Cancer Center/Children’s Hospital and Regional Medical Center, 2001- present.

*Director*, Pediatric Infection Control; *Assistant Director*, Infection Control, University of Chicago Hospitals, 1998-2002.

*Director*, Pediatric and Adolescent HIV Health Care Team, University of Chicago; *Liason* with Department of Obstetrics and Internal Medicine.

*Infectious Disease Representative*, Bone Marrow Transplant Team, University of Chicago, 1998-2002.

*Director*, Pediatric Fellowship Training Program in Infectious Diseases, University of Chicago 2000-2002.

**Research Funding: ACTIVE**

**ENGLUND**

**Seattle Children's Hospital** 12/20/2012-9/1/2013 Research support  
Clinical Significance of rhinovirus detected by PCR in pediatric patients seeking medical Care  
Study funded by Clinical and Translational Research Center to determine RhV viral load, subtypes, and clinical importance of Rhinovirus in patients seeking medical care at SCH.  
Role: Co-investigator

**ENGLUND**

5/1/12-4/30/14

0.5 calendar

**PATH**

RSV surveillance and antibody levels in Southeast Asia

Study funded by Gates Fndn/PATH to determine epidemiology of RSV disease in pregnant women and infants in Nepal using RSV PCR, and RSV maternal antibody transmission to infants born in Bangladesh and Nepal.  
Role: PI

**ENGLUND**

CDC contract

8/1/11-7/31/15

2.40 calendar

**New Vaccine Surveillance Network** [2011: \$450,000]

Federal contract to study effectiveness of new vaccines in population-based screening as part of a 5-unit CDC-sponsored consortium  
Role: PI at Seattle Children's

**ENGLUND**

1/1/08-12/31/14

1.20 calendar

NIH contract

\$4,020,000 [2009: \$538,000]

**NIH Vaccine and Treatment Evaluation Unit**, Subcontract to ----(b)(4)----- (-----)(b)(4)(b)(6)-----)

Federal contract to study new vaccines and new populations for current vaccines and treatments  
Role: PI of Seattle Children's subcontract

**ENGLUND**

BM Gates Foundation

1/2009-12/2013

2.40 Calendar

**"Maternal Immunization to protect the Mother and Neonate"** (Subsite-Cincinnati Children's Hospital)

Grant to evaluate the impact of maternal influenza immunization in rural areas of developing countries in Asia  
Role: Site principal Investigator; laboratory liaison

**ENGLUND**

4/7/09-4/6/14

0.75 calendar

NIH contract

[2009: \$382,463]

**NIH Operation of a Facility for the Study of Infectious Agents, Vaccines, and Antimicrobials**,

Subcontract to Johns Hopkins HHSN272200900010c

Federal contract to study new respiratory vaccines derived from intramural NIH research laboratories  
Role: PI of Children's subcontract

ENGLUND05A0 (J. Englund)

07/01/05-06/30/09

0.60 calendar

Cystic Fibrosis Foundation

---(b)(4)(b)(6)--- (No cost extension through 2010)

**Role of Viruses in CF Airway Infections**

Pilot study to evaluate the role of respiratory viral infections and bacterial infection in CF patients.  
Role: PI

No Number (J. Englund)

4/01/08-03/30/10

0.36 calendar

MedImmune, Inc.

---(b)(4)(b)(6)---

**The Impact of Viruses Disease in Daycare Centers.**

Estimate the incidence of respiratory and enteric virus infection in infants attending fulltime daycare.

Role: Local Site PI and project PI (Co-investigator, -----(b)(6)-----)

No Number (J. Englund) 2/07- 2/10 0.05 calendar

Collaborative Antiviral Study Group (NIH-NIAID) \$48,600

**Pharmacokinetic/pharmacodynamic and safety evaluation of oseltamivir for the treatment of children < 24 months with influenza (CASG 114).**

Role: Local Site PI, Member of Study Team

No Number (J. Englund) 8/08- 8/10 0.05 calendar

Collaborative Antiviral Study Group (NIH-NIAID) \$177,000

**Phase II randomized, placebo-controlled, blinded investigation of 6 weeks vs. 6 months of oral valganciclovir therapy in infants with symptomatic ocongenital cytomegalovirus infection (CASG 112).**

Role: Local Site PI, Member of Study Team

#### **COMPLETED, IN REVIEW:**

R01 HL081595 (Boeckh, Michael) 09/19/05-7/30/09 1.20 calendar

NIH/NIAID \$70,712

**Respiratory Viruses and Airflow Obstruction after HCT**

This study will determine impact and mechanisms of respiratory virus-associated airflow obstruction after hematopoietic stem cell transplant

Role: Co-PI; Subsite of Fred Hutchinson Cancer Research Center

No Number (J. Englund) 03/21/06-03/20/08 0.24 calendar

MedImmune, Inc. --(b)(4)(b)(6)--

**A Phase I Randomized Double-Blind Trial of the Safety and Immunogenicity of FluMist a Live, Intranasal Influenza Virus Vaccine vs. Placebo in Immunocompromised Children Ages 5 -17 Years**

Describe the safety of FluMist compared with placebo in immunocompromised children with cancer.

Role: Local Site PI, Co-Investigator (one of 4 sites involved)

No Number (J. Englund) 09/01/05-08/31/07 0.60 calendar

Sanofi Pasteur, Inc. --(b)(4)(b)(6)--

**Safety and Immunogenicity of Fluzone Influenza Virus Vaccine (2005-2006 Formulation) Among Healthy Children -----(b)(4)----- of Age, ---(b)(4)---**

To demonstrate the safety of inactivated influenza vaccine vs placebo in ---(b)(4)---old children.

Role: Project PI, site PI, and primary author of manuscript in progress

No Number (J. Englund) 10/01/05-04/30/07 0.36 calendar

MedImmune, Inc. --(b)(4)(b)(6)--

**The Impact of Respiratory Viruses in Infants in Fulltime Daycare.**

Estimate the incidence of respiratory virus infection in infants attending fulltime daycare.

Role: Local Site PI, Project PI, and senior author of manuscripts in process

No Number (J. Englund) 02/21/06-02/02/08 0.24 calendar

Sanofi Pasteur, Inc. --(b)(4)(b)(6)--

**Comparison in US Adolescents of the Safety and Immunogenicity of Two Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccines: ADACEL\* and BOOSTRIX\*1.**

Evaluate the safety and immunogenicity of ADACEL and BOOSTRIX vaccines among US adolescents.

Role: Local Site PI, Project PI, and primary author of manuscript in progress

## BIBLIOGRAPHY

### MANUSCRIPTS IN REFEREED (PEER-REVIEWED) JOURNALS:

1. **Englund JA**, Lucas RV Jr. Cardiac complications in children with systemic lupus erythematosus. *Pediatrics*. 1983 Nov;72(5):724-730.
2. **Englund JA**, Brenningstall GN, Heck LJ, Lazuck JS, Karabatsos N, Calisher CH, Tsai TF. Diagnosis of western equine encephalitis in an infant by brain biopsy. *Pediatr Infect Dis*. 1986 May-Jun;5(3):382-384.
3. **Englund JA**, Fletcher CV, Johnson D, Chinnock B, Balfour HH Jr. Effect of blood exchange on acyclovir clearance in an infant with neonatal herpes. *J Pediatr*. 1987 Jan 110(1):151-153.
4. Bean B, Fletcher C, **Englund J**, Lehrman SN, Ellis MN. Progressive mucocutaneous herpes simplex infection due to acyclovir-resistant virus in an immunocompromised patient: correlation of viral susceptibilities and plasma levels with response to therapy. *Diagn Microbiol Infect Dis*. 1987 Jul, 7(3):199-204.
5. Jackson JB, Erice A, **Englund JA**, Edson JR, Balfour HH Jr. Prevalence of cytomegalovirus antibody in hemophiliacs and homosexuals infected with human immunodeficiency virus type 1. *Transfusion*. 1988 Mar-Apr;28(2):187-189.
6. **Englund JA**, Sullivan CJ, Jordan MC, Dehner LP, Vercellotti GM, Balfour HH Jr. Respiratory syncytial virus infection in immunocompromised adults. *Ann Intern Med*. 1988 Aug 1; 109(3):203-208.
7. Sharp HL, Lindahl JA, Freese DK, Burke B, **Englund J**, Johnson D, Johnson SB, Holman RT. A new hepato-pancreato-renal disorder resembling tyrosinemia involving neuropathy and abnormal metabolism of polyunsaturated acids. *J Pediatr Gastroenterol Nutr*. 1988 Mar-Apr;7(2):167-176.
8. Erice A, Hertz MI, Snyder LS, **Englund J**, Edelman CK, Balfour HH Jr. Evaluation of centrifugation cultures of bronchoalveolar lavage fluid for the diagnosis of cytomegalovirus pneumonitis. *Diagn Microbiol Infect Dis*. 1988 Aug;10(4):205-212.
9. **Englund JA**, Suarez CS, Kelly J, Tate DY, Balfour HH Jr. Placebo-controlled trial of varicella vaccine given with or after measles-mumps-rubella vaccine. *J Pediatr*. 1989 Jan; 114(1):37-44.
10. Fletcher CV, **Englund JA**, Bean B, Chinnock B, Brundage DM, Balfour HH Jr. Continuous infusion of high-dose acyclovir for serious herpesvirus infections. *Antimicrob Agents Chemother*. 1989 Aug;33(8):1375-1378.
11. Sia EO, **Englund JA**, Sannerud K, Hansen K, Shah N, Balfour HH Jr. Recovery of human immunodeficiency virus type 1 from supernatant fluid of routine viral cultures. *J Clin Microbiol*. 1989 Jul;27(7):1664-1666.
12. Hertz MI, **Englund JA**, Snover D, Bitterman PB, McGlave PB. Respiratory syncytial virus-induced acute lung injury in adult patients with bone marrow transplants: a clinical approach and review of the literature. *Medicine (Baltimore)*. 1989 Sep;68(5):269-281.
13. Schutze GE, **Englund JA**, Bresee JS. *Pseudomonas aeruginosa* endogenous endophthalmitis in a neonate. *Pediatr Infect Dis J*. 1989 Dec;8(12):893-895.



14. **Englund JA**, Zimmerman ME, Swierkosz EM, Goodman JL, Scholl DR, Balfour HH Jr. Herpes simplex virus resistant to acyclovir. A study in a tertiary care center. *Ann Intern Med.* 1990 Mar 15; 112(6):416-422.
15. Balfour HH Jr, Kelly JM, Suarez CS, Heussner RC, **Englund JA**, Crane DD, McGuirt PV, Clemmer AF, Aepli DM. Acyclovir treatment of varicella in otherwise healthy children. *J Pediatr.* 1990 Apr;116(4):633-639.
16. Engel JP, **Englund JA**, Fletcher CV, Hill EL. Treatment of resistant herpes simplex virus with continuous-infusion acyclovir. *JAMA.* 1990 Mar 23-30;263(12):1662-1664.
17. **Englund JA**, Piedra PA, Jefferson LS, Wilson SZ, Taber LH, Gilbert BE. High-dose, short-duration ribavirin aerosol therapy in children with suspected respiratory syncytial virus infection. *J Pediatr.* 1990 Aug;117(2 Pt 1):313-320.
18. **Englund JA**, Arvin AM, Balfour HH Jr. Acyclovir treatment for varicella does not lower gpI and IE-62 (p170) antibody responses to varicella-zoster virus in normal children. *J Clin Microbiol.* 1990 Oct;28(10):2327-2330.
19. **Englund JA**, Anderson LJ, Rhame FS. Nosocomial transmission of respiratory syncytial virus in immunocompromised adults. *J Clin Microbiol.* 1991 Jan;29(1):115-119.
20. **Englund JA**, Fletcher CV, Balfour HH Jr. Acyclovir therapy in neonates. *J Pediatr.* 1991 Jul; 119(1):129-135.
21. Fletcher CV, **Englund JA**, Edelman CK, Gross CR, Dunn DL, Balfour HH Jr. Pharmacologic basis for high-dose oral acyclovir prophylaxis of cytomegalovirus disease in renal allograft recipients. *Antimicrob Agents Chemother.* 1991 May;35(5):938-943.
22. Atmar RL, **Englund JA**, Hammill H. Complications of measles during pregnancy. *Clin Infect Dis.* 1992 Jan;14(1):217-226.
23. Glezen WP, **Englund JA**, Siber GR, Six HR, Turner C, Shriver D, Hinkley CM, Falcao O. Maternal immunization with the capsular polysaccharide vaccine for *Haemophilus influenzae* type b. *J Infect Dis.* 1992 Jun;165(Suppl 1):S134-S136.
24. Peltier MK, Filipovich AH, Bechtel M, Dirksen CL, **Englund JA**. Randomized double-blinded comparison of three intravenous immunoglobulin products in bone marrow transplantation. *Semin Hematol.* 1992 Jul;29(3 Suppl 2):112-115.
25. **Englund JA**, Glezen WP, Barreto L. Controlled study of a new five-component acellular pertussis vaccine in adults and young children. *J Infect Dis.* 1992 Dec;166(6):1436-1441.
26. Filipovich AH, Peltier MH, Bechtel MK, Dirksen CL, Strauss SA, **Englund JA**. Circulating cytomegalovirus (CMV) neutralizing activity in bone marrow transplant recipients: comparison of passive immunity in a randomized study of four intravenous IgG products administered to CMV-seronegative patients. *Blood.* 1992 Nov 15;80(10):2656-2660.
27. Woods CR, **Englund J**. Congenital toxoplasmosis presenting with eosinophilic meningitis. *Pediatr Infect Dis J.* 1993 Apr;12(4):347-348.

28. **Englund JA**, Mbawuike IN, Hammill H, Holleman MC, Baxter BD, Glezen WP. Maternal immunization with influenza or tetanus toxoid vaccine for passive antibody protection in young infants. *J Infect Dis*. 1993 Sep;168(3):647-656.
29. **Englund JA**, Decker MD, Edwards KM, Pichichero ME, Steinhoff MC, Anderson EL. Acellular and whole-cell pertussis vaccines as booster doses: a multicenter study. *Pediatrics*. 1994 Jan;93(1):37-43.
30. Vallejo JG, **Englund JA**, Garcia-Prats JA, Demmler GJ. Ganciclovir treatment of steroid-associated cytomegalovirus disease in a congenitally infected neonate. *Pediatr Infect Dis J*. 1994 Mar;13(3):239-241.
31. **Englund JA**, Piedra PA, Ahn YM, Gilbert BE, Hiatt P. High-dose, short-duration ribavirin aerosol therapy compared with standard ribavirin therapy in children with suspected respiratory syncytial virus infection. *J Pediatr*. 1994 Oct;125(4):635-641.
32. **Englund JA**, Glezen WP, Turner C, Harvey J, Thompson C, Siber GR. Transplacental antibody transfer following maternal immunization with polysaccharide and conjugate *Haemophilus influenzae* type b vaccines. *J Infect Dis*. 1995 Jan;171(1):99-105.
33. Anderson EL, Decker MD, **Englund JA**, Edwards KM, Anderson P, McInnes P, Belshe RB. Interchangeability of conjugated *Haemophilus influenzae* type b vaccines in infants. *JAMA*. 1995 Mar 15;273(11):849-853.
34. Whimbey E, Champlin RE, **Englund JA**, Mirza NQ, Piedra PA, Goodrich JM, Przepiorka D, Luna MA, Morice RC, Neumann JL, et al. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. *Bone Marrow Transplant*. 1995 Sep;16(3):393-399.
35. Edwards KM, Meade BD, Decker MD, Reed GF, Rennels MB, Steinhoff MC, Anderson EL, **Englund JA**, Pichichero ME, Deloria MA. Comparison of 13 acellular pertussis vaccines: overview and serologic response. *Pediatrics*. 1995 Sep;96(3):548-557.
36. Decker MD, Edwards KM, Steinhoff MC, Rennels MB, Pichichero ME, **Englund JA**, Anderson EL, Deloria MA, Reed GF. Comparison of 13 acellular pertussis vaccines: adverse reactions. *Pediatrics*. 1995 Sep;96(3):557-566.
37. **Englund JA**, Anderson EL, Reed GF, Decker MD, Edwards KM, Pichichero ME, Steinhoff MC, Rennels MB, Deforest A, Meade BD. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. *Pediatrics*. 1995 Sep;96(3):580-584.
38. Deloria MA, Blackwelder WC, Decker MD, **Englund JA**, Steinhoff MC, Pichichero ME, Rennels MB, Anderson EL, Edwards KM. Association of reactions after consecutive acellular or whole-cell pertussis vaccine immunizations. *Pediatrics*. 1995 Sep;96(3):592-594.
39. Steinhoff MC, Reed GF, Decker MD, Edwards KM, **Englund JA**, Pichichero ME, Rennels MB, Anderson EL, Deloria MA, Meade BD. A randomized comparison of reactogenicity and immunogenicity of two whole-cell pertussis vaccines. *Pediatrics*. 1995 Sep;96(3):567-570.

40. Rennels MB, Reed GF, Decker MD, Edwards KM, Pichichero ME, Deloria MA, **Englund JA**, Anderson EL, Steinhoff MC, Deforest A, et al. Simultaneous administration of *Haemophilus influenzae* type b vaccine with acellular or whole-cell pertussis vaccine: effects on reactogenicity and immune responses to pertussis vaccines. *Pediatrics*. 1995 Sep;96(3):576-579.
41. Pichichero ME, Christy C, Decker MD, Steinhoff MC, Edwards KM, Rennels MB, Anderson EL, **Englund JA**. Defining the key parameters for comparing reactions among acellular and whole-cell pertussis vaccines. *Pediatrics*. 1995 Sep;96(3):588-592.
42. Whimbey E, Couch RB, **Englund JA**, Andreeff M, Goodrich JM, Raad II, Lewis V, Mirza N, Luna MA, Baxter B, et al. Respiratory syncytial virus pneumonia in hospitalized adult patients with leukemia. *Clin Infect Dis*. 1995 Aug;21(2):376-379.
43. Rowen JI, **Englund JA**. Brucellosis presenting with cough. *Pediatr Infect Dis J*. 1995 Aug;14(8):721-722.
44. Whimbey E, Champlin RE, Couch RB, **Englund JA**, Goodrich JM, Raad I, Przepiorka D, Lewis VA, Mirza N, Yousuf H, Tarrand JJ, Bodey GP. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. *Clin Infect Dis*. 1996 May;22(5):778-782.
45. Park MK, **Englund JA**, Glezen WP, Siber GR, Nahm MH. Association of placental transfer of anti-*Haemophilus influenzae* type b polysaccharide antibodies with their V regions. *Vaccine*. 1996 Sep;14(13):1219-1222.
46. **Englund JA**, Piedra PA, Jewell A, Patel K, Baxter BB, Whimbey E. Rapid diagnosis of respiratory syncytial virus infections in immunocompromised adults. *J Clin Microbiol*. 1996 Jul;34(7):1649-1653.
47. Lewis VA, Champlin R, **Englund J**, Couch R, Goodrich JM, Rolston K, Przepiorka D, Mirza NQ, Yousuf HM, Luna M, Bodey GP, Whimbey E. Respiratory disease due to parainfluenza virus in adult bone marrow transplant recipients. *Clin Infect Dis*. 1996 Nov;23(5):1033-1037.
48. **Englund JA**, Baker CJ, Raskino C, McKinney RE, Lifschitz MH, Petrie B, Fowler MG, Connor JD, Mendez H, O'Donnell K, Wara DW, AIDS Clinical Trials Group Protocol 152 Study Team. Clinical and laboratory characteristics of a large cohort of symptomatic, human immunodeficiency virus-infected infants and children. *Pediatr Infect Dis J*. 1996 Nov;15(11):1025-1036.
49. Garcia R, Raad I, Abi-Said D, Bodey G, Champlin R, Tarrand J, Hill LA, Umphrey J, Neumann J, **Englund J**, Whimbey E. Nosocomial respiratory syncytial virus infections: prevention and control in bone marrow transplant patients. *Infect Control Hosp Epidemiol*. 1997 Jun;18(6):412-416.
50. Pichichero ME, Deloria MA, Rennels MB, Anderson EL, Edwards KM, Decker MD, **Englund JA**, Steinhoff MC, Deforest A, Meade BD. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. *Pediatrics*. 1997 Nov;100(5):772-788.
51. **Englund JA**, Baker CJ, Raskino C, McKinney RE, Petrie B, Fowler MG, Pearson D, Gershon A, McSherry GD, Abrams EJ, Schliozberg J, Sullivan JL, AIDS Clinical Trials Group (ACTG) Study 152 Team. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. *N Engl J Med*. 1997 Jun 12;336(24):1704-1712.

52. **Englund JA**, Glezen WP, Thompson C, Anwaruddin R, Turner CS, Siber GR. *Haemophilus influenzae* type b-specific antibody in infants after maternal immunization. *Pediatr Infect Dis J*. 1997 Dec;16(12):1122-1130.
53. Yousuf HM, **Englund J**, Couch R, Rolston K, Luna M, Goodrich J, Lewis V, Mirza NQ, Andreeff M, Koller C, Elting L, Bodey GP, Whimbey E. Influenza among hospitalized adults with leukemia. *Clin Infect Dis*. 1997 Jun;24(6):1095-1099.
54. Palumbo PE, Raskino C, Fiscus S, Pahwa S, Fowler MG, Spector SA, **Englund JA**, Baker CJ. Predictive value of quantitative plasma HIV RNA and CD4<sup>+</sup> lymphocyte count in HIV-infected infants and children. *JAMA*. 1998 Mar 11; 279(10): 756-761.
55. **Englund JA**, Champlin RE, Wyde PR, Kantarjian H, Atmar RL, Tarrand J, Yousuf H, Regnery H, Klimov AI, Cox NJ, Whimbey E. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. *Clin Infect Dis*. 1998 Jun;26(6):1418-1424.
56. **Englund J**, Glezen WP, Piedra PA. Maternal immunization against viral disease. *Vaccine*. 1998 Aug-Sep;16(14-15):1456-1463.
57. Palumbo PE, Raskino C, Fiscus S, Pahwa S, Schutzbank T, Spector SA, Baker CJ, **Englund JA**. Virologic and immunologic response to nucleoside reverse-transcriptase inhibitor therapy among human immunodeficiency virus-infected infants and children. *J Infect Dis*. 1999 Mar;179(3):576-583.
58. Keitel WA, Muenz LR, Decker MD, **Englund JA**, Mink CM, Blumberg DA, Edwards KM. A randomized clinical trial of acellular pertussis vaccines in healthy adults: dose-response comparisons of 5 vaccines and implications for booster immunization. *J Infect Dis*. 1999 Aug;180(2):397-403.
59. Raskino C, Pearson DA, Baker CJ, Lifschitz MH, O'Donnell K, Mintz M, Nozyce M, Brouwers P, McKinney RE, Jimenez E, **Englund JA**, Pediatric AIDS Clinical Trials Group 152 Study Team. Neurologic, neurocognitive, and brain growth outcomes in human immunodeficiency virus-infected children receiving different nucleoside antiretroviral regimens. *Pediatrics*. 1999 Sep;104(3):e32.
60. Munoz FM, Campbell JR, Atmar RL, Garcia-Prats J, Baxter BD, Johnson LE, **Englund JA**. Influenza A virus outbreak in a neonatal intensive care unit. *Pediatr Infect Dis J*. 1999 Sep;18(9):811-815.
61. Ghosh S, Champlin R, Couch R, **Englund J**, Raad I, Malik S, Luna M, Whimbey E. Rhinovirus infections in myelosuppressed adult blood and marrow transplant recipients. *Clin Infect Dis*. 1999 Sep;29(3):528-532.
62. Jefferson LS, Coss-Bu JA, **Englund JA**, Walding D, Stein F. Respiratory system mechanics in patients receiving aerosolized ribavirin during mechanical ventilation for suspected respiratory syncytial viral infection. *Pediatr Pulmonol*. 1999 Aug;28(2):117-124.
63. Pichichero ME, Edwards KM, Anderson EL, Rennels MB, **Englund JA**, Yerg DE, Blackwelder WC, Jansen DL, Meade BD. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children. *Pediatrics*. 2000 Jan;105(1):e11.
64. Rennels MB, Deloria MA, Pichichero ME, Losonsky GA, **Englund JA**, Meade BD, Anderson EL, Steinhoff MC, Edwards KM. Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines. *Pediatrics*. 2000 Jan;105(1):e12.

65. Altman CA, **Englund JA**, Demmler G, Drescher KL, Alexander MA, Watrin C, Feltes TF. Respiratory syncytial virus in patients with congenital heart disease: a contemporary look at epidemiology and success of preoperative screening. *Pediatr Cardiol*. 2000 Sep-Oct;21(5):433-438.
66. Rennels MB, **Englund JA**, Bernstein DI, Losonsky GA, Anderson EL, Pichichero ME, Munoz FM, Wolff MC. Diminution of the anti-polyribosylribitol phosphate response to a combined diphtheria-tetanus-acellular pertussis/*Haemophilus influenzae* type b vaccine by concurrent inactivated poliovirus vaccination. *Pediatr Infect Dis J*. 2000 May;19(5):417-423.
67. Barroga CF, Raskino C, Fangon MC, Palumbo PE, Baker CJ, **Englund JA**, Spector SA. The *CCR5Δ32* allele slows disease progression of human immunodeficiency virus-1-infected children receiving antiretroviral treatment. *J Infect Dis*. 2000 Aug;182(2):413-419.
68. Pearson DA, McGrath NM, Nozyce M, Nichols SL, Raskino C, Brouwers P, Lifschitz MC, Baker CJ, **Englund JA**, Pediatric AIDS clinical trials 152 study team. Predicting HIV disease progression in children using measures of neuropsychological and neurological functioning. *Pediatrics*. 2000 Dec;106(6):e76.
69. Ghosh S, Champlin RE, **Englund J**, Giralt SA, Rolston K, Raad I, Jacobson K, Neumann J, Ippoliti C, Mallik S, Whimbey E. Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin. *Bone Marrow Transplant*. 2000 Apr;25(7):751-755.
70. Lindsey JC, Hughes MD, McKinney RE, Cowles MK, **Englund JA**, Baker CJ, Burchett SK, Kline MW, Kovacs A, Moye J. Treatment-mediated changes in human immunodeficiency virus (HIV) type 1 RNA and CD4 cell counts as predictors of weight growth failure, cognitive decline, and survival in HIV-infected children. *J Infect Dis*. 2000 Nov;182(5):1385-1393.
71. Berkelhamer S, Borock E, Elsen C, **Englund J**, Johnson D. Effect of highly active antiretroviral therapy on the serological response to additional measles vaccinations in human immunodeficiency virus-infected children. *Clin Infect Dis*. 2001 Apr 1;32(7):1090-1094.
72. Dankner WM, Lindsey JC, Levin MJ; Pediatric AIDS Clinical Trials Group Protocol Teams 051, 128, 138, 144, 152, 179, 190, 220, 240, 245, 254, 300 and 327 (**Englund, JA**). Correlates of opportunistic infections in children infected with the human immunodeficiency virus managed before highly active antiretroviral therapy. *Pediatr Infect Dis J*. 2001 Jan;20(1):40-48.
73. Pichichero ME, Anderson EL, Rennels MB, Edwards KM, **Englund JA** [sic]. Fifth vaccination with diphtheria, tetanus and acellular pertussis is beneficial in four- to six-year-olds. *Pediatr Infect Dis J*. 2001 Apr;20(4):427-433.
74. Santosham M, **Englund JA**, McInnes P, Croll J, Thompson CM, Croll L, Glezen WP, Siber GR. Safety and antibody persistence following *Haemophilus influenzae* type b conjugate or pneumococcal polysaccharide vaccines given before pregnancy in women of childbearing age and their infants. *Pediatr Infect Dis J*. 2001 Oct;20(10):931-940.
75. Munoz FM, **Englund JA**, Cheesman C, Maccato M, Pinell P, Nahm MH, Mason EO, Kozinetz CA, Thompson R, Glezen WP. Maternal immunization with pneumococcal polysaccharide vaccine in the third trimester of gestation. *Vaccine*. 2002;20:826-837.

76. Cohen NJ, Oram R, Elsen C, **Englund JA**. Response to changes in antiretroviral therapy after genotyping in human immunodeficiency virus-infected children. *Pediatr Infect Dis J*. 2002 Jul;21(7):647-653.
77. Yu J, Briles DE, **Englund JA**, Hollingshead SK, Glezen WP, Nahm MH. Immunogenic protein contaminants in pneumococcal vaccines. *J Infect Dis*. 2003 Mar 15;187(6):1019-1023.
78. Mongkolrattanothai K, Oram R, Redleaf M, Bova J, **Englund JA**. Tuberculous otitis media with mastoiditis and central nervous system involvement. *Pediatr Infect Dis J*. 2003 May;22(5):453-456.
79. Capparelli EV, **Englund JA**, Connor JD, Spector SA, McKinney RE, Palumbo P, Baker CJ. Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children. *J Clin Pharmacol*. 2003 Feb;43(2):133-140.
80. Nahm MH, Glezen P, **Englund J**. The influence of maternal immunization on light chain response to *Haemophilus influenzae* type b vaccine. *Vaccine*. 2003 Jul 28;21(24):3393-3397.
81. **Englund JA**. Maternal immunization with inactivated influenza vaccine: rationale and experience. *Vaccine*. 2003 Jul 28;21(24):3460-3464.
82. **Englund JA**, Glezen WP. Maternal immunization with *Haemophilus influenzae* type b vaccines in different populations. *Vaccine*. 2003 Jul 28;21(24):3455-3459.
83. Chantry CJ, Byrd RS, **Englund JA**, Baker CJ, McKinney RE Jr; Pediatric AIDS Clinical Trials Group Protocol 152 Study Team. Growth, survival and viral load in symptomatic childhood human immunodeficiency virus infection. *Pediatr Infect Dis J*. 2003 Dec;22(12):1033-1039.
84. **Englund JA**, Raskino C, Vavro C, Palumbo P, Ross LL, McKinney R, Nikolic-Djokic D, Colgrove RC, Baker CJ; The Pediatric AIDS Clinical Trials Group Protocol 152 Team. Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors. *Pediatr Infect Dis J*. 2004 Jan;23(1):15-22.
85. Tsuang WM, Bailar JC, **Englund JA**. Influenza-like symptoms in the college dormitory environment: a survey taken during the 1999-2000 influenza season. *J Environ Health*. 2004 Apr;66(8):39-42, 44.
86. Behari P, **Englund J**, Alcasid G, Garcia-Houchins S, Weber SG. Transmission of methicillin-resistant *Staphylococcus aureus* to preterm infants through breast milk. *Infect Control Hosp Epidemiol*. 2004;25(9):778-780.
87. Scott JD, **Englund JA**, Myerson D, Geballe AP. Influenza a pneumonia presenting as progressive focal infiltrates in a stem cell transplant recipient. *J Clin Virol* 2004;31(2):96-99.
88. Johnson LN, Han JY, Moskowitz SM, Burns JL, Qin X, **Englund JA**. *Pandoraeba bacteremia* in a cystic fibrosis patient with associated systemic illness. *Pediatr Infect Dis J* 2004;23(9):881-882.
89. Imhof A, Balajee SA, Fredricks DN, **Englund JA**, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. *Clin Infect Dis* 2004;39(5):743-746.

90. DeVincenzo JP, Hall CB, Kimberlin DW, Sanchez PJ, Rodriguez WJ, Jantusch BA, Corey L, Kahn JS, **Englund JA**, Suzich JA, Palmer-Hill FJ, Branco L, Johnson S, Patel NK, Piazza FM. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants. *J Infect Dis* 2004;190(5):975-978.
91. Randolph AG, Reder L, **Englund JA**: Risk of bacterial infection in previously healthy respiratory syncytial virus-infected young children admitted to the intensive care unit. *Pediatr Infect Dis J* 2004;23:990-994.
92. Forsyth KD, Campins-Marti M, Caro J, Cherry JD, Greenberg D, Guiso N, Heininger U, Schellekens J, Tan T, von Konig CH, Plotkin S (**Global Pertussis Initiative**): New pertussis vaccination strategies beyond infancy: recommendations by the global pertussis initiative. *Clin Infect Dis* 2004;39:1802-1809.
93. Wendelboe AM, Van Rie A, Salmaso S, **Englund JA**. Duration of immunity against pertussis after natural infection or vaccination. *Pediatr Infect Dis J* 2005;24:S58-61.
94. Van Rie A, Wendelboe AM, **Englund JA**. Role of maternal pertussis antibodies in infants. *Pediatr Infect Dis J* 2005;24:S62-65.
95. Boeckh M, Erard V, Zerr D, **Englund J**. Emerging viral infections after hematopoietic cell transplantation. *Pediatr Transplant* 9 Suppl 2005;7:48-54.
96. **Englund JA**, Walter EB, Fairchok MP, Monto AS, Neuzil KM:. A comparison of 2 influenza vaccine schedules in 6- to 23-month-old children. *Pediatrics* 2005;115:1039-1047.
97. **Englund JA**, Boeckh M, Kuypers J, Nichols WG, Hackman RC, Morrow RA, Fredricks DN, Corey L. Fatal human metapneumovirus infection in stem-cell transplant recipients. *Ann Intern Med* 2006;144:344-349.
98. **Englund JA**, Walter EB, Gbadebo A, Monto AS, Zhu Y, Neuzil KM: Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers. *Pediatrics* 2006;118:e579-585.
99. Gerber SI, Jones RC, Scott MV, Price JS, Dworkin MS, Filippelli MB, Rearick T, Pur SL, McAuley JB, Lavin MA, Welbel SF, Garcia-Houchins S, Bova JL, Weber SG, Arnow PM, **Englund JA**, Gavin PJ, Fisher AG, Thomson RB, Vescio T, Chou T, Johnson DC, Fry MB, Molloy AH, Bardowski L, Noskin GA. Management of outbreaks of methicillin-resistant *Staphylococcus aureus* infection in the neonatal intensive care unit: a consensus statement. *Infect Control Hosp Epidemiol* 2006;27:139-145.
100. King JC, Jr., Stoddard JJ, Gaglani MJ, Moore KA, Magder L, McClure E, Rubin JD, **Englund JA**, Neuzil K. Effectiveness of school-based influenza vaccination. *N Engl J Med* 2006;355:2523-2532.
101. Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, **Englund JA**: Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming? *Pediatrics* 2006;118:e570-578.
102. Boeckh M, **Englund J**, Li Y, Miller C, Cross A, Fernandez H, Kuypers J, Kim H, Gnann J, Whitley R: Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. *Clin Infect Dis* 2007;44:245-249.

103. Kuypers J, Martin ET, Heugel J, Wright N, Morrow R, **Englund JA**. Clinical disease in children associated with newly described coronavirus subtypes. *Pediatrics* 2007;119:e70-76.
104. Qin X, Galanakis E, Martin ET, **Englund JA**. Multi-target Polymerase Chain Reaction for Diagnosis of Pertussis and Its Clinical Implications. *J Clin Microbiol* 2007;45:506-11
105. Galankas E, **Englund JA**, Abe P, Qin X. Antimicrobial susceptibility of *Bordetella pertussis* isolates in the state of Washington. *Int J Antimicrob Agents* 2007;29:609-11.
106. Heugel J, Kuypers J, Martin E, **Englund JA**. Coronavirus-associated pneumonia in previously healthy children. *Pediatr Inf Dis J* 2007, 26:753-5.
107. Peck A, **Englund JA**, Kuypers J, Guthrie K, Corey L, Morrow R, Cent A, Boeckh M. Respiratory Virus Infection among Hematopoietic Cell Transplantation Recipients: Evidence for Asymptomatic Parainfluenza Virus Infection. *Blood* 2007,110:1681-8.
108. Vu D, Peck AJ, Nichols WG, Varley C, **Englund JA**, Corey L, Boeckh M. Safety and tolerability of oseltamivir prophylaxis in hematopoietic cell transplantation recipients: A retrospective case-control study. *Clin Infect Dis* 2007, 45:187-93.
109. Tasian SK, Park JR, Martin ET, **Englund JA**. Influenza-associated morbidity in children with cancer. *Ped Cancer*, 2008;50(5):983-7 [Epub Jan 2008].
110. Zerr DM, **Englund JA**, Robertson AS, Marcuse EK, Garrison MM, Christakis DA. Hospital-based influenza vaccination of children: An opportunity to prevent subsequent hospitalization. *Pediatrics* 2008;121:345-8
111. Kunz A, **Englund JA**, Kuypers J, Maranich A, Fairchok MP. Detection of Multiple Respiratory Viruses by Real-Time Polymerase Chain Reaction in Infants Attending an Outpatient Clinic. *Eur J Clin Micro Infect Dis* 2008; 27:1245-8.
112. Qin X, Zerr DM, Weissman SJ, **Englund JA**, Denno DM., Klein EJ, Tarr PI, Kwong J, Stapp JR, Tulloch LG, Galanakis E. Prevalence and mechanisms of broad-spectrum  $\beta$ -lactamase Resistance in *Enterobacteriaceae*: a Children's Hospital experience. *Antimicrob Agents Chemo* 2008;52:3909-14.
113. Martin ET, Kuypers J, Heugel J, **Englund JA**. Clinical disease and viral load in children infected with respiratory syncytial virus or human metapneumovirus. *Diagn Micro Infect Dis* 2008; 62:382-8.
114. Verghese PS, Finn LS, **Englund JA**, Sanders JE, Hingorani S. BK nephropathy in pediatric hematopoietic stem cell transplant recipients. *Pediatric Transplantation* 2009; 13:913-8.
115. Stempel H, Martin ET, Kuypers J, **Englund JA**, Zerr DM. Multiple viral respiratory pathogens in children with bronchiolitis. *Acta Paediatrica* 2009; 98:123-6.
116. Djokic D, **Englund J**, Daum R, Martin R, Dozier T, Potts S, Verber L, Marcinak J. HIV knowledge and attitudes toward HIV testing of South Side Chicago Housing Authority residents. *AIDS Patient Care* 2009; 23:23-27.
117. Scott A, Harper SA, Bradley JA, **Englund JA**, File TM, Gravenstein S, Hayden FG, McGeer AJ, Neuzil KM, Pavia AT, Tapper ML, Uyeki TM, Zimmerman RK. Seasonal Influenza in Adults and Children—



Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management: Clinical Practice Guidelines of the Infectious Diseases Society of America. *J Infect Dis* 2009; 48:1003-32.

118. Walter EB, **Englund JA**, Blatter M, Nyberg J, Ruben FL, Decker MD, and the GRC 27 Study Team. Trivalent Inactivated Influenza Virus Vaccine Given to 2 Month-Old Children: A Pilot Study. *Pediatric Infect Dis J* 2009; 28:1099-1104.
119. Rasmussen SA, Jamieson DJ, MacFarlane K, Cragan JD, Williams J, Henderson A, and the Pandemic Influenza and Pregnancy Working Group. Pandemic Influenza: Special considerations for pregnant women- Summary of a meeting of experts. *Amer J Public Health* 2009;99(S2): 1-7.
120. Shurtleff DB, Loeser J D, Avellino AM, Duguay S,B, **Englund JA**, Marcuse EK, MD, Peterson D, *Haemophilus influenzae* and *Streptococcus pneumoniae* Infections in Children with Cerebrospinal Fluid Shunts. *Pediatr Neurosurg* 2009;45:276-80.
121. National Center for Immunization and Respiratory Diseases, CDC; Centers for Disease Control and Prevention (CDC). Use of influenza A(H1N1 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. *MMWR Recomm Rep*. 2009 Aug 28;58(RR-10):1-8. (**J Englund**, Collaborator)
122. Centers from Disease Control, with contributions from **Englund J**, Zerr D, Heath J, Pergam S, Kuypers J, Yager J, Boeckh M, Mattson D, Whittington N, Whimbey, Duchin J, Uyeki T, Dyde V, Okomo-Adhiambo M, Sheu T, Trujillo A, Klimov A, Gubareva L, Kay M. *MMWR Dispatch – Oseltamivir-Resistant Novel Influenza A (H1N1) Virus Infection in Two Immunosuppressed Patients-Seattle, WA* 2009. *MMWR* 58:1-3 (Aug. 14, 2009)
123. Martin ET, Taylor J, Kuypers J, Magaret A, Wald A, Zerr D, **Englund JA**. Detection of bocavirus in saliva of children with and without respiratory illness. *J Clin Micro* 2009;47:4131-2.
124. **Englund JA**, Walter E, Black S, Blatter M, Nyberg J, Ruben FL, Decker MD, and the GRC 28 Study Team. Placebo-controlled Study of the Safety and Immunogenicity of Trivalent Inactivated Influenza Vaccine in Infants. *Pediatr Infect Dis* 2010;29:105-10.
125. Milano F\*, Campbell AP\*, Guthrie KA, Kuypers J, **Englund JA**, Corey L, Boeckh M. Human rhinovirus and coronavirus detection among allogeneic hematopoietic stem cell transplantation recipients. *Blood* 2010;115:2088-94. (\*contributed equally)
126. Casper C, **Englund J**, Boeckh M. How I treat influenza in patients with hematological malignancies. *Blood* 2010;115(7):1331-42.
127. Kimberlin DW, Shalabi M, Abzug MJ, Lang D, Jacobs RF, Storch G, Bradley JS, Wade K, Ramilo O, Romero JR, Shelton M, Leach D, Guzman-Cottrill J, Robinson J, Abughali N, **Englund J**, Griffin J, Jester P, Cloud GA, Whitley RJ for the NIAID Collaborative Antiviral Study Group. Safety of oseltamivir vs. adamantanes in children under 12 months of age: A retrospective chart review. *Pediatr Infect Dis* 2010; 29:195-8.
128. Campbell AP, Chien JW, Kuypers J, **Englund JA**, Wald A, Guthrie K, Corey L, Boeckh M. Respiratory virus pneumonia after hematopoietic cell transplantation: Viral load in bronchoalveolar lavage and detection in serum. *J Infect Dis* 2010;201:1404-13.

129. Martin ET, Fairchok MP, Kuypers J, Magaret A, Zerr D, Wald A, **Englund JA**. Frequent and prolonged shedding of bocavirus in young children attending daycare. *JID* 2010; 201:1625-32.
130. Walter EB, Rajagopal S, Zhu Y, Neuzil KM, Fairchok MP, **Englund JA**. Trivalent Inactivated Influenza Vaccine (TIV) Immunogenicity in Children 6 through 23 Months of Age: Do Children of All Ages Respond Equally? *Vaccine* 2010; 28:4376-83.
131. Singleton RJ, Bulkow LR, Miernyk K, DeByle C, Pruitt L, Boyd-Hummel K, Bruden D., **Englund JA**, Anderson L, Lucher L, Holman RC, Hennessy TW. Viral Respiratory Infections in Hospitalized and Community Control Children in Alaska. *J Med Virol* 2010; 82:1282-90.
132. Campbell AP, Jacob ST, Bohling SD, Kuypers J, Wald A, **Englund JA**, Corey L, Boeckh M. Respiratory failure caused by 2009 novel influenza A/H1N1 in a hematopoietic stem-cell recipient: Detection of extrapulmonary H1N1 RNA and use of intravenous peramivir. *Ann Intern Med* 2010;152: 619-620.
133. Burroughs LM, Torgerson TR, Storb R, Carpenter PA, Rawlings D, Sanders J, Scharenbarg A, Skoda-Smith S, **Englund JA**, Ochs HD, Woolfrey AE. Stable Hematopoietic Cell Engraftment using a Low-Intensity Nonmyeloablative Conditioning in Patients with Complicated Immune dysregulation, Polyendocrinopathy, Enteropathy, X-linked (IPEX) Syndrome. *J All Clin Imm* 2010; 126:1000-5.
134. Taylor JA, Weber WJ, Martin ET, McCarty RL, **Englund JA**. Development of a symptom score to identify children with a documented viral upper respiratory tract infection. *Ped Res* 2010; 68:252-7.
135. Fairchok MP, Martin ET, Chambers S, Kuypers J, Behrens M, Braun LE, **Englund JA**. Epidemiology of Viral Respiratory Tract Infections in a Prospective Cohort of Infants and Toddlers Attending Daycare. *J Clin Vir* 2010; 49: 16-20.
136. Waitumbi J, Kuypers J, Anyona SB, Koros JN, Polhemus ME, Gerlach J, Steele M, **Englund JA**, Neuzil KM, Domingo GJ. Outpatient viral upper respiratory tract infections in children with malaria symptoms in western Kenya. *Am J Trop Med*, 2010; 83:1010-3.
137. Renaud C, Pergam SA, Polyak C, Jain R, Kuypers J, **Englund JA**, Corey L, Boeckh MJ. Early emergence of an H275Y mutation in a hematopoietic cell transplant recipient treated with intravenous peramivir. *Transplant Infect Dis* 2010; Nov. 1-5.
138. Boudreault A, Xie H, Leisenring WM, **Englund JA**, Boeckh M. Impact of Corticosteroid Treatment and Antiviral Therapy on Clinical Outcomes in Hematopoietic Cell Transplant Patients Infected with Influenza Virus. *Biol Blood BMT* 2011;17:979-86.
139. Renaud C, Boudreault A, Kuypers J, Lofy K, Corey L, Boeckh M, **Englund JA**. H275Y mutant pandemic H1N1 2009 virus in immunocompromised patients. *Emerg Inf Dis* 2011; 17:653-60.
140. M Kay, Zerr D, **Englund JA**, Cadwell BL, Kuypers J, Swenson P, Kwan-Gett TS, Duchin J. 2009 Pandemic Influenza A (H1N1) Among Health Care Personnel — Duration of Viral Shedding and Implications for Exclusion Recommendations. *Emerg Infect Dis* 2011;17: 639-44.
141. Fairchok MP, Martin MT, Kuypers J, **Englund JA**. Parainfluenza Virus 4 Infections in a Prospective Cohort of Infants and Toddlers Attending Daycare. *Pediatr Infect Dis* 2011;30:716-8.

142. Choi SM, Boudreault A, Xie H, **Englund JA**, Corey L, Boeckh M. Differences in clinical outcomes following influenza A/H1N1 and seasonal influenza among hematopoietic cell transplant recipients. *Blood* 2011;117:5050-6.
143. **Englund J**, Feuchtinger T, Ljungman P. Viral Infections in Immunocompromised Patients. *Biol Blood Marrow Transplant* 2011; 17 (1Suppl):S2-5.
144. Renaud C, Kuypers J, Ficken E, Cent A, Corey L, **Englund JA**. Introduction of a Novel Parechovirus RT-PCR Clinical Test in a Regional Medical Center. *J Clin Vir* 2011;51:50-3.
145. Halasa N, **Englund JA**, Nachman S, Weinberg GA, Huber VC, Allison K, Dubovsky F, Yi T, McCullers JA, Flynn PM. Safety of live attenuated influenza vaccine in mild to moderately immunocompromised children with cancer. *Vaccine* 2011; 29:4110-5.
146. Renaud C, Kuypers J, Aspesberro F, Rosenfeld M, **Englund JA**. Emergence of oseltamivir-resistant pandemic H1N1 in an immunocompetent child with severe status asthmaticus. *J Asthma* 2011;48:572-5.
147. Ortiz JR, **Englund JA**, Neuzil KM. Influenza vaccine for pregnant women in resource-constrained countries: A review of the evidence to inform policy decisions. *Vaccine* 2011;29:4439-52.
148. Feltes TF, Sondeheimer HM, Tulloh RM, Harris BS, Jensen KM, Losonsky GA, Griffin MP, Motavizumab Cardiac Study Group. A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease. *Ped Res* 2011; 70:186-91.
149. Renaud C, Kuypers J, **Englund JA**. Emerging oseltamivir resistance in seasonal and pandemic influenza A/H1N1. *J Clin Vir* 2011; 52:70-8.
150. Martin ET, Kuypers J, Wald A, **Englund JA**. Multiple versus single virus respiratory infections: Viral load and clinical disease severity in hospitalized children. *Influenza and Other Resp. Viruses* 2012; 6:71-77.
151. Renaud C, **Englund JA**. Antiviral therapy of respiratory viruses in hematopoietic stem cell transplant recipients. *Antiviral Therapy* 2012; 17(1 ptB):175-91.
152. Lundgren I, **Englund JA**, Burroughs LM, Torgerson TR, Skoda-Smith S. Outcomes and Duration of *Pneumocystis jirovecii* Pneumonia Therapy in Infants with Severe Combined Immunodeficiency. *Pediatr Infect Dis J* 2012; 95-7.
153. Burns JL, Emerson J, Kuypers J, Campbell AP, Gibson RL, McNamara S, Worrell K, **Englund JA**. Respiratory viruses in children with cystic fibrosis: Viral detection and clinical findings. *Influenza Other Resp Viruses* 2012;6:218-23. [PMID: 2195531]
154. Braun LE, Renaud C, Fairchok MP, Kuypers J, **Englund JA**, Martin ET. Human parechovirus and other enteric viruses in childcare attendees in the era of rotavirus vaccines. *J Pediatr Infect Dis Soc* 2012; 1: 136-143.

155. Fisher BT, Zaoutis TE, Park JR, **Englund JA**, Kane C, Arececi R, Guinan E, Park J, Bleakley M, Luan X, Smith F, Marr KA. Galactomannan Antigen Testing for Diagnosis of Invasive Aspergillosis in Pediatric Hematology Patients. *J Pediatr Infect Dis Soc* 2012; 1: 103-111.
156. Kim YJ, M Boeckh, Cook L, Stempel H, Jerome KR, Boucek Jr R, Burroughs L, **Englund JA**. Cytomegalovirus Infection and Ganciclovir Resistance due to UL97 Mutations in Pediatric Transplant Recipients. *Transplant Infect Dis* 2012;14:611-7. PMID 23198963
157. Kuypers J, Campbell AP, Guthrie KA, Wright NL, **Englund JA**, Corey L, Boeckh M. Wu and KI polyomaviruses in respiratory samples from allogeneic hematopoietic stem cell transplant recipients. *Emerg Inf Dis* 2012; 18:1580-8. PMID 23017213
158. Choi SM, Campbell AP, Kuypers J, Boudreault, **Englund JA**, Corey L, Boeckh M. Influenza viral RNA detection in blood as a marker to predict disease severity in hematopoietic cell transplant recipients. *J Inf Dis* 2012; 206:1872-7. PMID 23033148
159. Xu M, Qin X, Astion ML, Rutledge JC, Simpson J, Jerome KR, **Englund JA**, Zerr DM, Migita RT, Rich S, Childs JC, Cent A, Del Beccaro MA. Implementation of FilmArray respiratory viral panel in a core laboratory improves testing turn-around-time and patient care. *Am J Clin Path* 2013;139:118-123. PMID 23270907
160. Kimberlin DW, Acosta EP, Sánchez PJ, M.D. Ampofo K, Lang D, Vanchiere JA, **Englund JA**, Caserta MT, Sood S, Ashouri N, Abzug MJ, Michaels M, Abughali N, Spigarelli M, Wan W, Jester P, Griffin J, Lakeman FD, Whitley RJ, NIAID Collaborative Antiviral Study Group. Oseltamivir pharmacokinetics, dosing, and resistance among children aged < 2 years with influenza. *J Infect Dis* 2013; 207:709-20. PMID: 23230059
161. Campbell AP, Kuypers J, **Englund JA**, Guthrie K, Corey L, Boeckh M. Self Collection of Nasal Swab Samples for Respiratory Virus Diagnosis: Foam Swab with Saline Spray is a Reliable Method among Immunocompetent Subjects and Hematopoietic Stem Cell Transplant Recipients. *J Clin Micro* 2013;51:324-7. PMID: 23135933
162. Seo S, **JA Englund**, Nguyen JT, Pukrittayakamee S, Lindegardh N, Tarning J, Tambyah PA, Renaud C, Went GT, deJong MD, Boeckh MJ. Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: Safety and pharmacokinetics. *Antiviral Res*, 2013 [Epub ahead of print Dec. 21, 2012] PMID: 23264438
163. Martin EM, Fairchok MP, Stednick ZJ, Kuyers J, **Englund JA**. Epidemiology of multiple respiratory viruses in childcare attendees. *J Infect Dis*, 2013; 207:982-9. PMID: 23288925
164. -----  
------(b)(4)-----
165. Seo S, Campbell A, Xie H, Chien JW, **Englund JA**, Boeckh M. Outcome of Respiratory Syncytial Virus lower respiratory tract disease in hematopoietic cell transplant recipients: Significance of stem cell source and oxygen requirement. *Biol Blood Marrow Transplant* 2013;19:589-96. PMID:23298855

166. Chu HY, Kuypers J, Sarancino M, Wald A, Martin E, Fairchok M, **Englund JA**. Molecular epidemiology of respiratory syncytial virus transmission in childcare. *J Clin Vir* 2013; 57:343-50.
167. Renaud C, Kuypers J, Xie H, Cent A, Corey L, Boeckh M, **Englund JA**, Human metapneumovirus and respiratory syncytial virus lower respiratory tract infections in hematopoietic stem cell transplant recipients have high mortality rates. *BBMT*, 2013 (Epub ahead of print: May 13, S1083-8791).
168. -----  
----- (b)(4) -----  
-----

Redact 1 page (b)(4)

**BOOK CHAPTERS/REVIEWS/INVITED PAPERS:**

1. **Englund JA** and Balfour HH Jr. Antiviral Therapy of Varicella-Zoster Virus Infections. In: *Clinical Use of Antiviral Drugs*, E. DeClerq, Ed., Nijhoff Publishers, Boston, 127-143, 1988.
2. **Englund JA** and Balfour HH Jr. Varicella and Herpes Zoster. In: *Infectious Diseases*, 4th ed., PH Hoeprich and MC Jordan, editors, Harper and Row Publishers, Philadelphia, 942-953, 1989.
3. **Englund JA** and Baker CJ. Chemotherapeutic Approaches to Pediatric HIV Infection. In: *Seminars in Pediatric Infectious Diseases*, Ralph D. Feigin, editor, 1(1):130-139, 1990.
4. Rosenblatt HM, **Englund JA** and Shearer WT. Immunotherapeutic approaches to pediatric HIV infection. *Seminars in Pediatric Infectious Diseases*, 1(1):140-149, 1990.
5. **Englund JA** and Glezen WP. Maternal immunization for the prevention of infection in early infancy. *Seminars in Pediatric Infectious Diseases*, 2(3):225-231, 1991.
6. **Englund JA**, guest editor. "Travel Recommendations for Children, part I". In: *Seminars in Pediatric Infectious Diseases*, WB Saunders Co., Philadelphia, PA 3(1):2-69, 1992.
7. **Englund JA**, guest editor. "Travel Recommendations for Children, part II". In: *Seminars in Pediatric Infectious Diseases*. WB Saunders Co., Philadelphia, PA 3(2):70-139, 1992.
8. **Englund JA**. Varicella-Zoster Virus Infections. In: *Current Therapy in Pediatric Infectious Diseases*, SL Kaplan, editor, Mosby Yearbook, 265-269, 1993.
9. **Englund JA** and Balfour HH Jr. Varicella-Zoster infections. In: *Infectious Diseases*, 5th ed., PH Hoeprich and MC Jordan, editors, Harper and Row Publishers, Philadelphia, 952-962, 1994.
10. Nelson CT and **Englund JA**. New approaches to the use of ribavirin. *Seminars in Pediatric Infectious Diseases*, 7:114-120, 1996.
11. Piedra PA, **Englund JA** and Glezen WP. Respiratory syncytial virus and parainfluenza viruses. In: *Clinical Virology*, ed., F. Hayden, R. Whitley. 717-819, Churchill Livingstone, NY, 1997.
12. Atmar RL and **Englund JA**. Laboratory methods for the diagnosis of viral diseases. In: *Viral Infections of Humans*, 4th ed., AS Evans and RA Kaslow, editors, 59-82. Plenum Publishing Corp., New York, NY, 1997.
13. **Englund JA**. Prophylaxis and therapy of RSV and other community respiratory virus infections in immunocompromised hosts. *Cancer Research Therapy and Control*, 141-145, 1999; January.
14. **Englund JA**, Whimbey E and Atmar RA. Laboratory methods for the diagnosis of respiratory viral diseases. In: *Transplant Infections*. R. Bowden, P Ljungman and C. Paya, editors. 63-78. Lippincott-Raven Publishers, Philadelphia, PA. 1998.
15. Whimbey EE and **Englund JA**. Community respiratory virus infections in transplant recipients. in *Transplant Infections* R. Bowden, P Ljungman, and C. Paya, editors. 295-308. Lippincott-Raven Publishers, Philadelphia, PA , 1998.
16. Englund JA and King J. Respiratory Viral Infections (Chapter). In: *Pediatric AIDS: The Challenge of HIV Infection in Infants, Children, and Adolescents*, 3rd ed. 227-249. PA Pizzo, CW Wilfert, editors. Williams and Wilkins, Baltimore, MD, 1998.
17. **Englund JA**, Whimbey E and Atmar RL. Diagnosis of respiratory viruses in cancer and transplant patients. In: *Current Clinical Topics in Infectious Diseases*, Remington JS, Swartz MN, editors. Blackwell Publishing, Malden. 1999;19:30-59.
18. Munoz FM and **Englund JA**. A step ahead: infant protection through maternal immunization. *Pediatric Clinics of North America* 2000;47(2):449-463.

19. Crowe JE and **Englund JA**. Future strategies for the prevention of RSV. In: *Contemporary Diagnosis and Management of Respiratory Syncytial Virus Infection*. Groothuis J and Weisman LE, editors. Handbooks in Health Care, Newtown PA, 2000.
20. Munoz FM and **Englund JA**. Vaccines in pregnancy. *Infectious Disease Clinics of North America* 2001;15:253-273.
21. **Englund JA**. Antiviral Therapy for Influenza. *Seminars in Pediatric Infectious Diseases*, 2002;13(2):120-8.
22. **Englund JA** and Whimbey E. Community-Acquired Respiratory Viruses after Hemopoietic Stem Cell or Solid Organ Transplantation. *Transplant Infections*. R. Bowden, P Ljungman, and C. Paya, editors. Lippincott-Raven Publishers, Philadelphia, PA. 2003, 375-98.
23. Tan T, Halperin S, Cherry JD, Edwards K, **Englund JA**, Glezen P, Greenberg D, Rothstein E, Skowronski D. Pertussis immunization in the Global Pertussis Initiative North American region: recommended strategies and implementation considerations. *Pediatric Inf Dis J* 2005;24 (Suppl);S83-7.
24. Piedra PA, **Englund JA**, and Glezen WP. Respiratory syncytial virus and parainfluenza viruses. In: *Clinical Virology*, ed., D. Richman, F. Hayden, R. Whitley. ASM Press, 2003, 763-790.
25. Kim YJ, Boeckh M, **Englund JA**. Community Respiratory Virus Infections in Immunocompromised Patients: Hematopoietic Stem Cell and Solid Organ Transplant Recipients, and individuals with HIV Infection. *Seminars Resp Crit Care Med* 2007; 28: 222-42.
26. **Englund JA**. The influence of maternal immunization on infant immune responses. *J Comp Path* 2007;137: S16-S19.
27. Smith JM, **Englund JA**. “Immunizations in children undergoing dialysis” in *Handbook of Dialysis Therapy*. Editors, Missenson and Fine, Fourth Edition. Elsevier, 2007.
28. Burns J, **Englund JA**, Prince A. “Infectious Complications in Special Hosts.” In: *Pediatric Infectious Diseases*, Ed. Long S, Pickering L. Third Edition, 2008.
29. Williams JV, Piedra PA, and **Englund JA**. Respiratory syncytial virus, parainfluenza viruses, and human metapneumovirus. In: *Clinical Virology*, D. Richman, R/ Whitley, F. Hayden. ASM Press, 2009, 817-848.
30. Tomblyn, M, T Chiller, H Einsele, R Gress, K Sepkowitz, J Storek, JR Wingard, J-AH Young, MA Boeckh. Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplant Recipients: A Global Perspective. *Recommendations of the Center for International Blood and Marrow Transplant Research (CIBMTR®), the National Marrow Donor Program (NMDP), the European Blood and Marrow Transplant Group (EBMT), the American Society of Blood and Marrow Transplantation (ASBMT), the Canadian Blood and Marrow Transplant Group (CBMTG), the Infectious Disease Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the Association of Medical Microbiology and Infectious Diseases Canada (AMMI), the Centers for Disease Control and Prevention (CDC), and the Health Resources and Services Administration (HRSA)*. Jointly published in *Biology of Blood and Marrow Transplantation* 2009 Oct; 15 (10): 1143 – 1238; and *Bone Marrow Transplantation* 2009 Oct; 44 (8): part 2. (**JA Englund**, Contributor)
31. **Englund JA** and Whimbey E. Community-Acquired Respiratory Viruses after Hemopoietic Stem Cell or Solid Organ Transplantation. In: *Transplant Infections*. R. Bowden, P Ljungman, and D Snyderman, editors. Lippincott-Raven Publishers, Philadelphia, PA, 2010
32. **Englund JA**, Burns J. Chapter 108: “Infectious Complications in Special Hosts” (Chapter 108), in *Pediatric Infectious Diseases*, Ed. Long S., Pickering L. Elsevier , 4<sup>th</sup> Edition. 2012.
33. McIntosh K, **Englund JA**. Coronaviruses (Chapter), in Feigin and Cherry Textbook of Pediatric Infectious Diseases, Third Edition. 2013.
34. Atmar R, **Englund JA**. Rhinoviruses (Chapter), in Feigin and Cherry Textbook of Pediatric Infectious Diseases, Third Edition. 2013.
35. Chu H, **Englund JA**. Treatment and Prevention of Respiratory Syncytial Virus. (Chapter 12) Editors, B. Graham and L. Anderson, Challenges and Opportunities for Respiratory Syncytial Virus Vaccines, in Series: *Current Topics in Microbiology and Immunology*, 2013.

36. **Englund JA** and Moscona A. Parainfluenza Viruses (Chapter), in *Viral Infections of Humans*. Editors, Stanberry L and Kaslow RA, 5<sup>th</sup> Edition, 2013.

#### OTHER PUBLICATIONS (LETTERS/EDITORIALS):

1. Bean B and **Englund JA**. Treatment of varicella zoster virus infections. *Clin. Lab. Med.* 7:853-868, 1987.
2. Pomeroy C and **Englund JA**. Cytomegalovirus: Transmission and infection control. *Am. J. Infect. Control* 15:107-119, 1987.
3. **Englund JA**. The many faces of EBV. *Postgrad. Med.* 833:167-179, 1988.
4. Balfour, Jr. HH and **Englund JA**. Antiviral Drugs in Pediatrics. *Amer. J. Dis. Child.* 143:1307-1316, 1989.
5. **Englund JA**, and Matson DO. Update on measles: Incidence rises after long decline. *Ped. Virol.* 46(4): 1-4, 1989.
6. Knight V, Gilbert BE, Wyde PR, **Englund JA**. High dose-short duration ribavirin aerosol treatment: a review. *Bull. Internat. Union Tuberc. Lung Dis.* 66:97-102, 1991.
7. E. Whimbey, R Champlin, R Couch, **JA Englund**, P Piedra, N Mirza, J Goodrich, L Elting, and G Bodey. High Incidence of Respiratory Syncytial Virus (RSV) Disease in Bone Marrow Transplant (BMT) Recipients: Combination Therapy (Rx) with Aerosolized Ribavirin and Intravenous Immunoglobulin (IVIG). *Blood* 1993; 82 (10): Supplement, 425A.
8. **Englund JA**. Passive protection against RSV disease in infants: The role of maternal antibody. *Pediatr Infect Dis J.* 13:449-453, 1994.
9. **Englund JA**, PA Piedra, BE Gilbert. Letter: Cost of ribavirin therapy for respiratory syncytial virus infection. *J Pediatr* 1995;125:847
10. **Englund JA**, Piedra PA, Whimbey E. Prevention and treatment of respiratory syncytial virus and parainfluenza viruses in immunocompromised patients. *Am J Med* 1997;102(suppl 3a): 61-70.
11. Couch RB, **Englund JA**, Whimbey E. Respiratory viral infections in immuno-competent and immunocompromised persons. *Am J Med* 1997;102(suppl 3a): 3-10 .
12. Whimbey E, **Englund JA**, Couch RB. Community respiratory virus infections in the immunocompromised patients with cancer. *Am J Med* 1997;102 (Supplement 3a): 10-18.
13. **Englund, JA**. Passive and Active Immunization for the Prevention of Respiratory Syncytial Virus Disease. *Current Concepts in the Use of Pediatric Vaccines*, RS Daum, Editor, Univ. of Chicago Children's Hospital Report, 1999.
14. **Englund, JA**. Prevention strategies for respiratory syncytial virus: Passive and active immunization. *J Pediatr* 1999; 135 (Supplement):S38-44
15. **Englund J**. Vacunas antipertussis acelulares: Presente y futuro. *Rev Chil Infect* 1999;16(supl 1):64-71.
16. **Englund J**. Vacunacion de la embarazada: Optimizar la proteccion del neonato. *Rev Chil Infect* 1999;16 (Supl 1):72-79.
17. **Englund, JA** and Glezen WP. Passive immunization for the prevention of otitis media. *Vaccine* 2000; 19;Suppl.116-121.
18. **Englund JA**. Diagnosis and epidemiology of Community-Acquired Respiratory virus infections in the immunocompromised host. *Biology of Blood and Marrow Transplantation* 2001(suppl);7:2s-4s.
19. Nikolic-Djokic D, **Englund JA**. Current status of respiratory syncytial virus vaccine. *New Developments in Vaccine Research* 2002; 2:20-28.
20. **Englund JA**. Maternal immunization with inactivated influenza vaccine: Rationale and Experience. *Vaccine* (2003).
21. **Englund JA** and Glezen WP. Maternal immunization with *Hemophilus influenza* type b vaccines in different populations. *Vaccine* 2003;21: 3455-3459.
22. **Englund J**. In search of a vaccine for respiratory syncytial virus: the Saga continues. Editorial, *J Infect Dis* 2005, 191:1036-9.



23. **Neuzil K, Englund JA.** Influenza vaccine for young children: Two doses are better than one. Editorial, *J Pediatr* 2006 Dec;149:737-8.
24. Martin ET, Fairchok MP, **Englund JA.** Reply to Longin et al: Otitis Media and Bocavirus. Correspondence, *J Infect Dis* 2010; 202(15 Nov)1617-8.
25. M Boeckh, **Englund JA.** Evaluation of therapeutics for RSV: An important step forward. (Editorial) *Am J Respir Crit Care Med* 2010;182:1-2.
26. Munoz F, **Englund JA.** Infant Pertussis: Is Cocooning the Answer? *Clin Infect Dis* 2011;53:893-6.
27. **Englund J.** From the President of the Pediatric Infectious Diseases Society. *J Pediatr Infect Dis Soc* 2012; 1: 2.
28. Shulman S, **Englund JA.** A conversation with Janet Englund, MD. *Pediatric Annals* 2012;41:7.
29. **Englund JA,** Munoz. Pertussis vaccine: It takes a village. *J Pediatr Inf Dis Soc* 2013;2:183-5.
30. **Englund JA,** Karron R, Dennehy P, Kimberlin D. Carolyn Breese Hall Obituary. *J Pediatr Inf Dis Soc* 2013;2:95-6.
31. **Schlaudecker EP,** Englund JA, Kimberlin DW. Update from the Advisory Committee on immunization Practices. *J Pediatr Infect Dis Soc* 2013;3: 97-99.

#### **INVITED LOCAL AND NATIONAL PRESENTATIONS (SINCE 1996):**

- January 29, 1996: Invited Symposium Speaker, Pediatric Treatment of HIV Infection: Preliminary Results of ACTG 152. Third Conference on Retroviruses and Opportunistic Infections, Washington, DC.
- February 18, 1996: FDA Advisory Committee on Antiretroviral Therapy. Invited guest speaker with Carol Baker, M.D: "Results of ACTG Study 152".
- September 15, 1996: Co-chairman, Community Respiratory Virus Infections in the Immunocompromised Host. Symposium sponsored by University TX- M.D. Anderson Cancer Center and NIAID. Treatment and Prophylaxis of RSV and Parainfluenza Virus Infections in the Immunocompromised Host. (*Am. J. Medicine supplement*, 1997).
- November 9, 1996: RSV in the Elderly and Immunocompromised, presented at the symposium, "RSV After 40 Years." Charleston, South Carolina.
- December 7, 1996: Diagnosis of Community Respiratory Viruses in Immunocompromised Hosts, Investigators' Meeting associated with American Society of Hematology, sponsored by MD Anderson Cancer Center and NIAID, Orlando, FL.
- December. 9, 1996: Clinical results of ACTG 152, Pediatric Plenary Session at the 22nd AIDS Clinical Trials Group Meeting, Washington, DC.
- January. 25, 1997: Prophylaxis and Therapy of RSV and other Community Respiratory Virus Infections in Immunocompromised Hosts, at Marrow Transplantation in Children - Current Results and Controversies. Fort Lauderdale, FL.
- February 24, 1997: Diagnosis of Community Respiratory Viruses in Immunocompromised Hosts, Investigators' Meeting- International Bone Marrow Transplant Society, Scottsdale, AZ.
- March 22, 1997: Pediatric Grand Rounds: "Current Status of Antiviral Therapy." Children's Hospital of Minneapolis, Minneapolis, MN.
- May 27, 1997: Immunizations 1997 - What's New. Houston Pediatric Society, Houston, TX.
- September 23, 1997: Group B Streptococcal Vaccines, sponsored by -----(b)(4)-----, Bethesda, MD.
- October 4, 1997: Update on RSV - Sponsored by University of AZ and MedImmune, Inc. Phoenix, AZ.
- October 31, 1997: "Immunizations for Children and Adults - What's New."
- November 14, 1997: Continuing Medical Education Course, Baylor College of Medicine, Dept. of Internal Medicine/Infectious Diseases, Houston, TX.
- October 15, 1998: "New Advances in RSV" – Pediatric Grand Rounds, University of Chicago Children's Hospital, Chicago, IL.

- November 7, 1998: “Prevention Strategies for RSV: Passive and Active Immunization” *RSV and Asthma: Is there a link?* Symposium, Washington, DC (cosponsored by ICN Pharm., Inc. and American Thoracic Society).
- February 5 and 24, 1999: “RSV and Asthma: Is there a link?” Children’s Hospital of Michigan, Detroit, MI and Children’s Medical Center of Dallas, Dallas, TX.
- March 19, 1999: “RSV Infections”, Sherman-St. Joseph Hospital, Elgin, IL.
- April 30, 1999: “Respiratory Infections in the Immunocompromised Host” University of South Carolina BMT Conference, Columbia, SC.
- July 9, 1999: “Respiratory Viruses” and “Enteroviruses and other Community Viruses”, at PREP: ID—An Intensive Review Course of Pediatric Infectious Diseases, sponsored by AAP. Chicago, IL.
- August 31, 1999. “Respiratory Viruses: Disease and Management” St. Elizabeth’s Hospital, Chicago, IL.
- September 23, 1999: Clinical Update in Pediatric Infectious Diseases, at Third Annual Pediatric Day, University of Chicago Children’s Hospital, Chicago, IL.
- September 29, 1999: Update in Pediatric Vaccines – Vaccines 2000 Conference, Carbondale, IL.
- April 26-29, 2000: Guest Speaker, National Pediatric Infectious Diseases Seminar. Lectures on influenza viruses, Hepatitis A virus, and antiviral chemotherapy.
- October 25, 2000: “Pneumococcal Disease and Prevention”, Victory with Vaccines – City of Chicago Dept. of Public Health. Chicago, IL.
- October 28, 2000: “Hepatitis C in the Pediatric Patient.” Speaker, AAP Annual Meeting, Chicago, IL.
- November 8, 2000: “Influenza: The Epidemics Continue.” Grand Rounds, U. TX-Southwestern, Dallas, TX.
- January 23, 2001: “Influenza: Update in Treatment and Prevention” Grand Rounds, Cook County Hospital, Chicago, IL.
- February 15, 2001: “Epidemiology and Diagnosis of Respiratory Viral Infections in the Immunocompromised Host”, Symposium at International Bone Marrow Transplant Meeting, Keystone, CO.
- March 14, 2001: “Hepatitis A” Grand Rounds, Illinois Masonic Hospital, Chicago, IL.
- March 28, 2001: “Hepatitis A” Grand Rounds, Mt. Sinai Hospital., Dept. Pediatrics, Chicago, IL.
- March 30, 2001: “Respiratory Viruses: New Drugs and New Vaccines”, Chicago Department of Public Health, Chicago, IL.
- July 13, 2001: “Respiratory Viruses” and “Enteroviruses and other Community Viruses”, at PREP: ID—An Intensive Review Course of Pediatric Infectious Diseases, sponsored by AAP. Chicago, IL.
- September 8, 2001: “Prevention of RSV Disease”, at 6<sup>th</sup> annual Update in RSV, Scottsdale, AZ.
- October 11, 2001: “Sexually Transmitted Diseases in Children and Adolescents” Sixth Annual Pediatric Day, University of Chicago Children’s Hospital, Chicago, IL.
- October 30, 2001: “Maternal Immunization”, Pediatric Infectious Disease Update: Monterey, CA.
- January 18, 2002: “Respiratory Viral Infections in Transplant Recipients” American Society of Transplantation, Squaw Valley, CA.
- January 25, 2002: “Respiratory Viruses in Children” Lake County Health Dept., Village, IL.
- February 23, 2002: “Diagnosis and Epidemiology of Respiratory Viruses” International Bone Marrow Transplant Society Symposium, Orlando, FL.
- March 15, 2002: “Respiratory Virus Infections in Patients. with Hematologic Malignancies and Stem Cell Transplantation. Fred Hutchinson Cancer Center, Seattle, WA.
- May 17, 2002: “Influenza – What’s New.” Pediatric Infectious Diseases of Chicago Symposium, Chicago, IL.
- November 2, 2002: “Pertussis and New Vaccines.” Update on Immunizations, Providence/St. Peter Hospital, Olympia, WA.
- December 2, 2002: “Update in Vaccines.” Alaska Health Summit sponsored by Alaska Public Health Association and Alaska Native Medical Center, Anchorage, AK.
- December 3, 2002: “Influenza Virus Infections: Prevention and Management.” Pediatric Grand Rounds, Alaska Native Medical Center, Anchorage, AK.
- July 10-11, 2003: “Respiratory Viruses” and “Enteroviruses and Other Community Viruses”, at PREP: ID—An Intensive Review Course of Pediatric Infectious Diseases, sponsored by AAP. Chicago, IL.

- October 13, 2003: “Influenza Vaccines: Especially for Children.” 10th Annual Joint Conference on Health, Washington State Public Health Association, Yakima, WA
- December 6, 2003: “Influenza in the Immunocompromised Host”, National meeting sponsored by Wyeth Vaccines, Las Vegas, NV.
- December 12, 2003: Rotavirus Vaccine Advisory Committee, Merck Vaccines, Inc., Westpoint, PA.
- January 27, 2004: Fred Hutchinson Cancer Research Center Grand Rounds “Human Metapneumovirus and Influenza in Transplant Recipients.”
- January 28, 2004: Univ. Washington Dept. of Laboratory Medicine: “What’s New with Respiratory Viruses.
- January 29, 2004: Seattle Children’s Hospital and Regional Medical Center, Dept. of Pediatrics Grand Rounds. “Maternal Immunization for the Prevention of Neonatal Disease.”
- February 6, 2004: Virginia Mason Medical Center Grand Rounds: “Update on Influenza.” Seattle, WA
- March 2-4, 2004, First International Neonatal vaccination Workshop, Speaker: “Maternal Immunization against RSV and Influenza Viruses,” McLean, VA.
- April 14-16, 2004: National Pediatric Infectious Disease Society Meeting, Guest Lecturer: “What is new with Influenza,” “Sexually Transmitted Diseases”, and “Maternal Immunization” Chicago, IL.
- April 16, 2004: Maternal Immunization for the Prevention of Neonatal Disease” Dept. of Obstetrics/Gynecology, University of Chicago, Chicago, IL.
- May 13-16, 2004: American Academy of Pediatrics “Practical Pediatrics CME” New and Emerging Pathogens, Practical Antiviral Therapy, Santa Fe, NM.
- October 9, 2004: AAP/Committee on Infectious Diseases: Treatment of Influenza, San Francisco, CA.
- November 20, 2004: Speaker, Respiratory Virus Symposium, “Respiratory Viruses”; “Prevention of RSV” at Respiratory Virus Symposium Kapiolani Hospital, Honolulu, HI
- March 17, 2005: Grand Rounds, “Update on Vaccines,” St. Peter’s Hospital, Olympia, WA.
- Nov. 27-29, 2005: Alaska Health Summit, Anchorage, AK. New Vaccines; Influenza Vaccination for All.
- Nov. 28, 2005: Grand Rounds, Alaska Native Medical Center, Anchorage, AK. What’s new with Pertussis.
- Jan 17, 2006: Speaker, St. Joseph’s Hospital, , “Influenza Vaccines” Tacoma, WA.
- Jan. 24, 2006: Speaker, Fred Hutchinson Cancer Research Center Grand Rounds – New Respiratory Viruses, Seattle, WA.
- April 19-22, 2006: National Pediatric Infectious Disease Seminar (NPIDS), New Respiratory Viruses; Antifungals, Influenza Virus. San Francisco, CA.
- May 22 and June 7, 2006: Speaker, Continuing Nursing Education, “RSV and Ribavirin,” University of Washington, Seattle, WA.
- Nov. 8, 2006 : Speaker, NIH meeting: Antivirals for Pandemic Influenza: “Vulnerable Populations”. Bethesda, MD.
- Jan. 19, 2007: Grand Rounds, “Pediatric Influenza,” Madigan Army Medical Center, Dept. Pediatrics, Tacoma, WA.
- March 6, 2007: Speaker, National Immunization Conference Satellite Symposium, “ Preventing Influenza in Children”, Kansas City, KS
- April 25, 2007: Clinical Investigator Speaker Series, “Recruitment and Retention of Patients in Clinical Trials”, University of Washington, Seattle, WA
- April 27, 2007: 27<sup>th</sup> Annual ID Symposium, Omaha, “New Respiratory Viruses,” University of Nebraska/Creighton University, Omaha, NE.
- May 20, 2007: Perinatal Action Committee of Washington, “Pandemic Influenza in Pregnant Women and Infants,” Renton, WA
- June 1, 2007: Puget Sound Association for Professionals in Infection Control, “New Findings in Influenza,,: Seatac, WA
- Sept. 18, 2007: Influenza in Daycare, invited speaker, IDSA, Chicago, IL
- Oct. 29-30, 2007: AAP Annual Meeting, San Francisco, CA: “Pandemic Influenza.”
- Jan. 11, 2008: Group Health Obstetric Grand Rounds, Seattle, WA: “Immunization to Protect the Mother and Infant”

- Feb. 22, 2008: Infections in the Immunocompromised Host Symposium, Houston, TX: “New Respiratory Viruses”
- Sept. 22, 2008: Maternal Immunization for the Protection of Mothers and Babies. Christiana Medical Center, Wilmington, DE
- Sept. 23, 2008: Immunizations for Infants. Grand Rounds and Visiting Professor at NemoursClinic/Dupont Children’s Hospital, Wilmington, DE
- Sept. 30, 2008: Alaska Native Medical Center Grand Rounds. New Respiratory Viruses and Respiratory Disease in Children. Anchorage, AK
- Oct. 2, 2008: Seattle Cityside Vaccine Forum, sponsored by the City Club, Seattle, WA.
- March 4, 2009: “Explaining vaccines to parents.” Pediatric Associates, Bellevue, WA
- March 10, 2009: Update on Human Papillomavirus Vaccine, Snohomish Health District, Everett WA
- April 3, 2009: RSV in the Immunocompromised Host. Minneapolis/St. Paul Children’s Hospital, Minneapolis, MN
- May 3, 2009: New Molecular Approaches for the Diagnosis of Viral Diseases, State of the Art Plenary Session, PAS/SPR 2009, Baltimore, MD.
- May 5, 2009: Antiviral Therapy of Influenza, Hot Topics Session, SPR/PAS 2009, Baltimore, MD
- May 15, 2009: Congenital CMV: Risk Factor for Childhood Hearing Loss. Universal Newborn Hearing Screening Meeting, Spokane, WA
- Nov. 4, 2009: Panelist, Infectious Diseases Society of Washington Fall Meeting: “Pandemic Influenza”
- Nov. 5, 2009: Panelist, Global Health 101, Seattle Biomedical Research Institute Lecture Series: “Influenza”
- Feb. 5, 2010: 2009 H1N1 Pandemic Influenza. Infectious Disease Sciences and Virology Division Annual Research Conference, Seattle, WA.
- July 13, 2010: Pandemic H1N1 Influenza in Children. At International Conference in Emerging Infectious Diseases, “Influenza in Special Populations”, Centers for Disease Control, Atlanta, GA.
- Sept. 9, 2010: Chartrand Memorial Lecture, Pediatric Grand Rounds, “Influenza,” Omaha, NE
- Oct. 7, 2010: American Academy of Pediatrics Annual Meeting, Plenary Session. “Influenza A/H1N1: A Pediatric Perspective,” San Francisco, CA
- Nov. 7, 2010: Influenza Vaccines for Women and Children. National Foundation of Infectious Diseases, Vaccinology Course, Bethesda, MD
- Feb. 18, 2011: Respiratory Viral Infections in Hematopoietic Transplant Recipients. American Society of Bone Marrow Transplant/Center for International BMT Research Tandem Meeting, Honolulu, HI.
- May 17, 2011: “Vaccination Strategies and Controversies: the Bumpy Road from Program Implementation towards Eradication.” Univ. Wash. Dept Epidemiology, Moderator and Speaker.
- May 18, 2011: “Vaccine Updates” for Infectious Disease Fellows Review Seminar, Seattle WA
- July 29, 2011: “Infections in Immunocompromised Hosts”, “Opportunistic Infections,” PREP ID Review course sponsored by AAP/ PIDS, Chicago, IL
- Nov. 16, 2011: “Respiratory Viral Infections in Children with Cancer” Grand Rounds, Children’s Hospital of Orange County, Los Angeles, CA.
- Jan. 24, 2012: “Diagnosis of Respiratory Viruses”, Dept. of Bioengineering, Univ. of Washington Graduate Student Seminar, Seattle, WA.
- Feb. 4, 2012: Immunization update: From Menactra to HPV; Immunization questions for the practitioner. 2012 Practical Pediatrics, Seattle Children’s Hospital, Seattle, WA.
- Feb. 7, 2012: “Respiratory Viral Infections in Immunocompromised Children.” Grand Rounds at Vanderbilt University Medical School, Dept. of Pediatrics, Nashville, TN.
- June 5, 2012: Update on New Vaccines, Port Angeles, WA.

**NATIONAL AND INTERNATIONAL ABSTRACT PRESENTATIONS (SINCE 2003):**

1. Nikolic-Djokic D, Elsen CA, Martin R, **Englund JA**. Knowledge and Attitudes about HIV Testing in Public Housing Residents on the South-Side of Chicago. 41st IDSA, Oct. 2003, San Diego,
2. Boeckh M, **Englund JA**, Kuypers J, et al. Randomized Controlled Multicenter Trial of Aerosolized Ribavirin for RSV Upper Respiratory Tract in Stem Cell Transplant Recipients. Presented Nov. 10, 2003, at RSV Symposium, Atlanta, GA.
3. **Englund JA**, Walters E, Fairchok M, Monto A, Neuzil K. Immunogenicity of Trivalent Inactivated Influenza Vaccine (TIV) in Toddlers Given a Spring-Fall Schedule vs a Standard 2-Dose Schedule. 42nd IDSA, Oct. 2004, Boston, MA Abstract #1018.
4. Walters E, Neuzil K, Fairchok M, **Englund JA**. Safety and Reactogenicity of Trivalent Inactivated Influenza Vaccine (TIV) in Toddlers Given a Spring-Fall Schedule vs a Standard 2-Dose Schedule. 42nd IDSA, Oct. 2004, Boston, MA. Abstract #1019
5. **Englund JA**, Kuypers J, Corey L, Ashley R, Cent A, Boeckh M. Asymptomatic Respiratory Virus Infection among Hematopoietic Cell Recipients. 43<sup>rd</sup> IDSA, Sept. 2005, San Francisco, CA
6. **Englund JA**, Walter E, Zhu Y, Monto AS, Gbadebo A, Neuzil K. Immunogenicity of one dose of trivalent inactivated influenza vaccine in partially immunized toddlers. 43<sup>rd</sup> IDSA, Sept. 2005, San Francisco, CA
7. Walter E, Neuzil K, Zhu Y, Fairchok M, Gagliano M, Monto A, **Englund J**. Influenza vaccine immunogenicity in 6-23 month old children: Are identical antigens necessary for priming? 43<sup>rd</sup> IDSA, Sept. 2005, San Francisco, CA
8. **Englund JA**, Kuypers J, Laux L, Zhu Y, Corey L, Morrow R. Quantitative respiratory syncytial virus RT-PCR in hospitalized children. Presented at International RSV 2005 Symposium, Oxford, England
9. Peck AJ, **Englund JA**, Kypers J, Corey L, Morrow R, Cent A, Boeckh M: Asymptomatic respiratory virus infection among hematopoietic cell recipients (Poster). Feb 26, 2006: ASBMT, Honolulu, HI.
10. **Englund JA**, Walsh E, Falsey A, Kim H, Corey L, Boeckh M. Impact of RSV neutralizing antibody levels on progression of upper respiratory tract disease in hematopoietic stem cell transplant recipient (Poster) Feb. 26, 2006, American Society of Bone Marrow Transplantation, Honolulu, HI.
11. Qin X., Galanakis E, **Englund JA**. Multi-target polymerase chain reaction increases diagnostic sensitivity for pertussis. Poster presentation, IDSA, Toronto, Oct. 13, 2006.
12. Vu D, Peck AJ, Nichols G, Varley C, **Englund J**, Corey L, Boeckh M. Oseltamivir prophylaxis in hematopoietic stem cell transplantation recipients: A Case-control study. IDSA, Toronto, Oct. 13, 2006.
13. Martin ET, Kuypers J, Heugel J, Morrow R, **Englund JA**. Quantitative evaluation of human metapneumovirus infection in children. Talk, presented at IDSA, Toronto, Oct. 13, 2006.
14. **Englund JA**, Walter EB, Black S, et al. Safety and Immunogenicity of Fluzone® Trivalent Inactivated Influenza Vaccine (TIV) in Infants 6-12 Weeks of Age. Presented at IDSA, Toronto, Oct. 14, 2006 (Abstract LB-1).
15. **Englund JA**. Infections in Daycare: Influenza. Symposium guest speaker. Presented at ICAAC, Chicago, IL, Sept. 15, 2007
15. **Presented or Supervisor of Presenter, IDSA 2007:**
  - a. Fairchok M, Chambers S, Kuypers J, Martin E, **Englund J**. Prospective study of viral respiratory tract infections in young hcildren attending daycare. Oral Presentation, IDSA San Diego 2007.
  - b. Kim YJ, **Englund JA**, Walsh E, Falsey A, Kirby K, Corey L, Boeckh M. Role of RSV neutralizing antibodies on progression of upper respiratory tract infection in hematopoietic cell transplant recipients. Poster presentation, IDSA San Diego, 2007.
  - c. Martin ET, Kuypers, Heugel J, **Englund JA**. Importance of respiratory viral coinfections in hospitalized children. Oral presentation, IDSA San Diego, 2007.
  - d. Peck AJ, **Englund JA**, Kuypers J, Corey L, Boeckh M. Respiratory virus pneumonia in hematopoietic cell transplant recipients: Viral load in bronchoalveolar lavage and blood. Poster, IDSA San Diego, 2007.

- e. Peck AJ, **Englund JA**, Bresee J, Lingappa J, Holman RC, Anderson LJ. Association of respiratory syncytial virus laboratory detections and pediatric hospitalizations for respiratory infections. Poster presentation, IDSA San Diego, 2007.
- f. Shalabi M, Abughali N, et al. Safety of oseltamivir vs. Amantadine or rimantadine in children under 1 year of age. Poster presentation, IDSA San Diego, 2007.
- g. Singleton R, Hennessy T, Bulkow L, Miernyk K, DeByle C, Boyd-Hummel K, Mosley M, Pruitt L, Holman R, Anderson L, **Englund J**. Unique seasonal patterns of respiratory virus hospitalizations in Alaska Native children. Poster presentation, IDSA San Diego, 2007
- h. Stempel H, Martin ET, Kuypers J, **Englund JA**, Zerr DM. Beyond RSV : The multiple pathogens of bronchiolitis. Oral presentation, IDSA San Diego, 2007.
- 16. **Englund JA**, Martin ET, Kuypers J, Chambers S, Fairchok M. Spread of RSV in Daycare. Presented at RSV International Symposium, Marcos Island, FL, Oct. 27, 2007.
- 17. Kim YJ, Boeckh M, Stempel H, Cook L, Jerome KR, Boucek R, Burroughs L, **Englund JA**. Cytomegalovirus Infection and Ganciclovir Resistance due to UL97 Mutation in Pediatric Transplant Recipients. Oral presentation at SPR, Honolulu, HI, May 6, 2008.
- 18. Presented at IDSA, October 2008, Washington, DC:
  - a. Walter EB, Zhu Y, Neuzil KN, **Englund JA**. Trivalent inactivated influenza vaccine (TIV) in young children: Effect of age on immunogenicity.
  - b. Singleton RS, Bulkow L, Debyle C, Miernyk, Pruitt L, Hennessy T, **Englund JA**. Viral Load Of Respiratory Syncytial Virus (RSV) In Children Hospitalized With Lower Respiratory Tract Infection (LRTI) Compared With Control Children.
  - c. Peck Campbell AJ, Kuypers J, **Englund JA**, Corey L, Boeckh M. Nasal Washes Put to the Test: Self Collection of Nasal Swabs for Diagnosis of Respiratory Viruses in Immunocompetent Volunteers
  - d. Angela J. Peck Campbell, Kuypers J, Nguyen P, **Englund JA**, Corey L, Boeckh M. Human Bocavirus (BoV) Detection in Nasal Washes of Hematopoietic Cell Transplantation (HCT) Recipients
  - e. Martin ET, Fairchok M, Kuypers J, **Englund JA**. High Prevalence of Bocavirus in Young Children Attending Daycare . Poster. Abstract # V416a- 10/28/2008
- 19. Milano F\*, Campbell AP\*, Kuypers J, Guthrie KA, **Englund JA**, Callais C, Corey L, and Boeckh M (\*contributed equally). Human Coronavirus and Rhinovirus Infection among Hematopoietic Stem Cell Transplantation Recipients. Poster presentation at the American Society of Bone Marrow Transplant/Center for International Blood and Marrow Transplant Research Tandem Meetings in Tampa, FL, February 12, 2009.
- 20. Kimberlin, D, Acosta, E, Sanchez, P, Ampofo, K, Vanchiere, J, **Englund, J**, Sood, S, Lang, D, Caserta, M, Abzug, M, Abughali, N, Michaels, M, Spigarelli, M, Wan, W, Jester, P, Griffin, J, Whitley, R, for NIAID Collaborative Antiviral Study Group (CASG). Oseltamivir pharmacokinetics (PK) in infants: Interim results from multicenter trial. 47<sup>th</sup> Annual Meeting of IDSA, Philadelphia, Pennsylvania, October 31, 2009.
- 21. Martin E, Taylor J, Kuypers J, Meier A, Wald A, Zerr D, **Englund JA**. Bocavirus detections in saliva of asymptomatic and symptomatic children. (Poster) 47<sup>th</sup> Annual Meeting of IDSA, Philadelphia, Pennsylvania, October 31, 2009.
- 22. Englund JA. Protecting vulnerable infants from influenza: Assessing Strategies - Immunization in Infants. Moderator and Speaker, IDSA 47<sup>th</sup> Annual Meeting, Oct. 31, 2009.
- 23. **Englund JA**, Boeckh M. A pilot randomized trial of combination oral amantadine, ribavirin, and oseltamivir (TCAD) versus oral oseltamivir for the treatment of influenza A virus in immunocompromised patients. International Conference on Antiviral Research (ICAR) Meeting, San Francisco, CA April 27, 2010 (presentation).
- 24. Presented /Supervisor, IDSA 2010:
  - a. Poster: #3138. Renaud C, Kuypers J, Ficken E, **Englund JA**. Introduction of a Novel Parechovirus RT-PCR in a Clinical Virology Laboratory

- b. Poster: #2988. Fairchok M, Martin ET, Kuypers J, Braun L, **Englund JA**. PIV4 Infections in a Daycare Setting
- c. Oral Presentation: # 2306. Kay M, Zerr D, **Englund JA**, Kwan-Gett TS, Bell S, Duchin J. Viral Shedding of 2009 Pandemic Influenza A (H1N1) Virus Among Health Care Personnel: Implications for Exclusion From Patient Care — Seattle, WA, 2009
- d. Oral Presentation: #3319. Martin ET, Kuypers J, Wald A, **Englund JA**, and Zerr DM. Intermittent and Persistent Shedding of Human Bocavirus (HBoV) in Saliva of Young Infants
- 25. Campbell AP, Minerich EL, Guthrie KA, Farney RM, Kuypers J, **Englund JA**, and Boeckh M. Clinical Outcomes Associated with Pre-Transplantation Respiratory Virus Infections. Poster, American Society of Bone Marrow Transplant/Center for International Blood and Marrow Transplant Research Tandem Meeting, Honolulu, HI; February 20, 2011. (Abstract 387)
- 26. Presented, SPR-PAS 2011:
  - a. Braun LE, Fairchok MP, Martin ET, Kuypers J, **Englund JA**. Human Parechovirus among infants attending large daycare centers in the Northwest United States. Poster #491, April 30, 2011, SPR, Denver, CO.
  - b. Lundgren IS, **Englund JA**, Burroughs LM, Torgerson TR, Skoda-Smith S. Duration and outcomes of pneumocystis jirovecii pneumonia therapy in infants with severe combined immunodeficiency. Poster # , SPR-PAS, Denver, CO May 1, 2011.
- 27. Presented, SPR-PAS 2012:
  - a. Wiltrakis SM, Cloud GA, Whitley RJ, Sánchez PJ, Ampofo K, Lang D, Ashouri N, Vanchiere JA, Abzug MJ, Abughali N, Caserta MT, **Englund JA**, Sood SK, Spigarelli MG, Bradley JS, Lew J, Michaels MG, Jester PM, Kimberlin DW. Predictors of Influenza Disease Severity and Resolution in Infants: Results of a National Collaborative Trial. Society for Pediatric Research (SPR), Boston, Massachusetts, April 28, 2012; Abstract 752603.
- 28. Poster presentation, Society for Immunotherapy of Cancer, Bethesda, MD. Arns K, Morishima C, Englund JA, et al. Selection of a control infectious disease vaccine for cancer immunotherapy trials. Oct. 26-28, 2012
- 29. Sept. 9, 2012: HPV Vaccines: For Girls and Boys”, speaker and moderator, ICAAC, San Francisco, CA.
- 30. Sept. 30, 2012: “Antiviral Therapy for RSV”, Speaker and moderator International RSV Symposium, Albuquerque, NM
- 31. Oct. 21, 2012: “Immunization for Influenza: Prevention Priorities.” IDSA Plenary Session, San Diego, CA
- 32. Oct. 5, 2013: Kimberlin DW, Jester PM, Sanchez PJ, Ahmed A, Arav-Boger R, Sood SK, Woods C, Ashouri N, **Englund JA**, Estrada B, Jacobs RF, et al. for the NIAID Collaborative Antiviral Study Group (CASG). Six months versus six weeks of oral valganciclovir for infants with symptomatic congenital cytomegalovirus disease with and without central nervous system involvement: Results of a Phase III, randomized, double-blind, placebo-controlled, multinational study. IDWeek 2013, *San Francisco, CA, Abstract #43178*- Late breaker oral presentation

#### INTERNATIONAL INVITED PRESENTATIONS (SINCE 1996):

- February 1-3, 1996: What's new with RSV; Meet the Professor. Update '96 Symposium: Clinical Management of Viral Infections. Vancouver, British Columbia, Canada.

- September 8-10, 1996: II International Consensus Symposium on Combined Antiviral Therapy and Implications for Future Therapies. "Pathogenesis and Treatment of Respiratory Viruses"; "Monotherapy and Combination Antiretroviral Therapy in Pediatric Patients." Barcelona, Spain.
- November 20, 1996: "RSV Bronchiolitis, the Baylor Experience," Imperial College School of Medicine at St. Mary's, London, and "Respiratory Viral Infections in the High Risk and Immunocompromised Patient", Great Ormond Street Hospital, London, England.
- December 4, 1996: "New Advances in the Management of HIV Infection in Children" given at the Satellite Symposium, "New Advances in the Management of Bacterial and HIV Infections in Children, 1st World Congress of Pediatric Infectious Diseases, Acapulco, Mexico.
- November 15, 1997: Invited speaker - "Maternal Immunization against Viral Diseases in Humans" given at the symposium "Immunity in Early Life," sponsored by Fondation Marcel Merieux/World Health Organization at Veyrier-du-Lac, France.
- January 26-27, 1998: Invited Panel Member - "Maternal Immunization with Pneumococcal Vaccines" - World Health Organization, Geneva, Switzerland, Jan. 26-27.
- January 28-29, 1998: "Viral Respiratory Disease in the Bone Marrow Transplant Recipient" - meetings held at Ludwig Maximalians Universitaet, Bone Marrow Transplant Unit, Munich, and Medizinische Fakultät der Humboldt Universität Virchow Klinikum, Berlin, Germany.
- February 9-10, 1998: "New Developments in RSV"; Meet the Professor. Update '98 Symposium: Clinical Management of Viral Infections. Vancouver, British Columbia, Canada.
- March 16-17, 1998: "Viral Respiratory Infections in the Immunocompromised Child" - Dept. of Pediatrics, Astrid Lindgren Children's Hospital; "Viral Respiratory Infections in the Immunocompromised Adult" Dept. of Infectious Diseases and Oncology, Internal Medicine, at Huddinge Hospital - Karolinska Institute, Stockholm, Sweden.
- March 20, 1998: "Viral Respiratory Infections in the Immunocompromised Patient." University of Helsinki - Aurora Hospital/Meiläke Hospital, Helsinki, Finland.
- June 10-11, 1998. Pediatric Infectious Disease Meeting, Santiago, Chile, to speak on: "Maternal Immunization and "Update on Acellular Pertussis Vaccines."
- June 22, 1998. "Community Respiratory Viral Infections in the Immunocompromised Host - Diagnosis and Pathogenesis of Respiratory Viruses." International Immunocompromised Host Society, Davos, Switzerland
- November 23, 1998: "RSV and Parainfluenza Virus Infections in the Bone Marrow Transplant Recipient – Diagnosis and Treatment" University of Utrecht Hospital, The Netherlands.
- February 24, 1999: Treatment and Prevention of RSV- European Infectious Disease conference, Madrid, Spain - sponsored by GlaxoWellcome.
- May 21, 1999: New Developments in Respiratory Viral Vaccines, presented at European Society for Pediatric Infectious Diseases, Crete, Greece; Moderator, Vaccine Section.
- September 13-15, 1999: Clinical Trial Design of HIV Antiretrovirals. Enwei Pharmaceuticals and Children's Hospital/Second University Hospital W. China University, Chengdu, Sichuan Province, China.
- February 6-8, 2000: What's new with RSV? At "Update 2000: Clinical Management of Viral Infections." Whistler, British Columbia.
- February 13-16, 2000: Passive Immunization for the Prevention of Otitis Media. Presented "Otitis Media: A Preventable Disease?" Sponsored by Fondation Marcel Merieux, Annecy, France.
- May 26-27, 2000: "RSV and Parainfluenza Infections in the Immunocompromised Host" at International Transplant Infectious Disease Conference, Stockholm, Sweden.
- June 19, 2000: "Infections in Immunocompromised Patients" Round Table, International Immunocompromised Host Society, Halifax, Nova Scotia, Canada.
- May 28, 2001: "Maternal Immunization," Second Advanced Vaccinology course co-sponsored by Fondation Merieux/WHO/CDC, Annecy, France.
- February 17-2, 2002: "Diagnosis of Respiratory Viruses" and "Update in RSV" at Update: 2002, Whistler: British Columbia.
- June 15-18, 2002: "Maternal Immunization," (Invited Faculty) Third Advanced Vaccinology course co-



sponsored by Fondation Merieux/WHO/CDC, Annecy, France.

- November 19-23, 2002: “Vaccination of Pregnant Women to Protect the Newborn” and “RSV in the Immunocompromised Host.” 3<sup>rd</sup> World Congress of Pediatric Infectious Diseases, Santiago, Chile.
- December 5-7, 2002: “Maternal Immunization: Immunology and Practice of Influenza Vaccines” and “Maternal Immunization with Hib Vaccines.” Organizing committee member and speaker, sponsored by Fondation Merieux/ World Health Organization, Annecy, France.
- June 6-11, 2003: “Pneumococcal Vaccines Workshop;” “Maternal Immunization,” Invited Faculty and Moderator, 4<sup>th</sup> Advanced Vaccinology course, sponsored by Fondation Merieux/WHO/CDC, Annecy, France.
- July 23 through 30, 2003. Invited Professor and Consultant, Muheza Regional Hospital, Tanzania. Lectures: Maternal Immunization, HIV in Children, and Respiratory Disease in Children.
- October 14, 2003: “Protection of Newborns through Maternal Immunization” Vaccinology Symposium, sponsored by Asociacion Panamericana de Infectologia; Sociedad Latinoamericana de Infectologia Pediatrica (SLIPE), Fondation Merieux, in Salvadore, Brazil.
- December 4, 2003: Global Advisory Committee on Vaccine Safety, World Health Organization. Participant, Influenza vaccine safety.
- February 7-9, 2004: Virology Update 2004. Clinical Course and Treatment of RSV” and Clinical Cases – Meet the Professor, Whistler Village, British Columbia, Canada.
- May 20, 2004: Englund JA, Neuzil KM, Fairchok M, Walter E. Comparison of two vaccine regimens for 6-23 month old children, Influenza Vaccines for the World, Portugal, 2004.
- May 16-18, 2004: “Pneumococcal Vaccines: Workshop;” “Maternal Immunization,” Invited Faculty and Moderator, Fifth Advanced Vaccinology course co-sponsored by Fondation Merieux/NIH/WHO/CDC, Annecy, France.
- Feb. 23-25, 2005: 2005 Annual Convention of the Pediatric Infectious Disease Society of the Philippines: Influenza, Maternal Immunization, Sexually Transmitted Diseases, Neonatal Infections, Manila, Philippines.
- June 1-4, 2005: “Maternal Immunization,” Invited Faculty and Moderator, Sixth Advanced Vaccinology course co-sponsored by Fondation Merieux/NIH/WHO/CDC, Annecy, France.
- September 16, 2005: Speaker, “Impact of RSV Neutralizing Antibody Levels on Progression of Upper Respiratory Tract Disease in Hematopoietic Stem Cell Transplant Recipients (HCT).” International RSV 2005 Symposium, Oxford, England
- May 24-25, 2006: “Maternal Immunization,” Invited Faculty and Moderator, 7th Advanced Vaccinology course co-sponsored by Fondation Merieux/NIH/WHO/CDC, Annecy, France.
- October 8-9, 2006: Meet the Professor – IDSA, Toronto, Canada.
- Nov. 2, 2006: Comparative Vaccinology Meeting: “Immunologic correlates of maternal antibody transmission” – Meryal Foundation, Athens, Greece.
- Jan. 11, 2007: Guest Speaker, “Prevention of Influenza,” Univ. British Columbia Vaccine Center, Canada.
- Jan. 12, 2007: Grand Rounds, “Respiratory Viral Diseases in the Immunocompromised Host,” Univ. British Columbia, Canada, Dept. Pediatrics.
- May 23-25, 2007: “Maternal Immunization,” Invited Faculty and Moderator, 8th Advanced Vaccinology course co-sponsored by Fondation Merieux/NIH/WHO/CDC, Annecy, France.
- Nov. 12, 2007: “Advances in Pediatric Influenza,” faculty speaker at World Society of Pediatric Infectious Diseases, Bangkok, Thailand.
- March 4-6, 2008: “Maternal Immunization,” invited faculty at Institut Pasteur, Dept. of Infectology and School of Public Health, Paris, France
- May 29, 2008: “Maternal Immunization,” Invited Faculty and Moderator, 9th Advanced Vaccinology course co-sponsored by Fondation Merieux/NIH/WHO/CDC, Annecy, France
- Nov. 18-20, 2008: “International workshop on Pertussis Surveillance program in Sweden”, invited participant, Karolinska Institut, Stockholm, Sweden.
- May 27-29, 2009: “Maternal Immunization,” Invited Faculty and Moderator, 10th Advanced Vaccinology course co-sponsored by Fondation Merieux/NIH/WHO/CDC, Annecy, France
- Nov. 19, 2009: “Infant Immunization against Influenza”, 6<sup>th</sup> World Congress of the World Society for

Pediatric Infectious Diseases, Buenos Aires, Argentina

- Dec. 5, 2009: Panelist, Influenza and Maternal Immunization in Developing Countries, Bamako, Mali. Hosted by Center for Vaccine Development- Mali and Gates Foundation.
- March 26-28, 2010: Moderator and Speaker, International Neonatal and Maternal Immunization Symposium. Influence of maternal influenza antibody on infant antibody responses; Epidemiology and Pathogenesis of RSV infection. Antalya, Turkey- sponsored by European Society for Pediatric Infectious Diseases, PATH.
- April 15-18, 2010: “Influenza,” “New Respiratory Viruses.” “Update in Vaccines” at Continuing Medical Education, Ascuncion, Paraguay, sponsored by the Paraguay Pediatric Association
- May 19-20, 2010: “Maternal Immunization,” Invited Faculty and Moderator, 10th Advanced Vaccinology course co-sponsored by Fondation Merieux/NIH/WHO/CDC, Annecy, France
- Oct 10-12, 2010: Meeting as member, SAGE Influenza Working Group at WHO, Geneva, Switzerland
- Dec. 4-5, 2010: “Maternal Immunization against Influenza”, Canadian Immunization 2010, Quebec City, Quebec, Canada
- March 15, 2011: “Definition of ILI in Maternal Influenza Vaccine Studies”, Gates Foundation Maternal Immunization Study Meeting, Kathmandu, Nepal.
- May 25-26, 2011: “Maternal Immunization,” Invited Faculty and Moderator, 12th Advanced Vaccinology course co-sponsored by Fondation Merieux/NIH/WHO/CDC, Annecy, France
- June 1-2: “Maternal Immunization” Strategic Meeting, Sponsored by Gates Foundation, London, England.
- Aug. 30, 2011: “Efficacy of Maternal immunization with influenza vaccine”, presented to SAGE Influenza working group of the World Health Organization, Geneva, Switzerland
- Sept 28-30, 2011: Lecturer at IndVac Vaccinology Course, Christian Medical College, Vellore, India. Seminars on: Influenza vaccines, Maternal Immunization, Vaccinations in Special Populations. Sponsored by Gates Fndn, WHO.
- Feb. 14, 2012: Immunity to influenza vaccines in children. Presented at WHO SAGE Influenza Advisory meeting, Geneva, Switzerland
- April 11, 2012: Effectiveness of Influenza Vaccine in High-Risk Populations. Presented at WHO SAGE meeting, Geneva, Switzerland
- May 25, 2012: “Maternal Immunization,” Invited Faculty and Moderator, 13th Advanced Vaccinology course co-sponsored by Fondation Merieux/NIH/WHO/CDC, Annecy, France
- May 26, 2012: “Safety of Influenza Vaccines during Pregnancy” presented to Pregnancy subcommittee of Global Advisory Committee on Vaccine Safety, World Health Organization, Geneva, Switzerland.
- June 18, 2012: “Maternal Immunization Update.” National Immunization Meeting, Darwin, Australia.
- Sept 25, 2012: “Influence of maternal immunization on infant antibody response.” Maternal Immunization, Challenges and Opportunities, Fondation Merieux, Annecy France.
- Dec. 3, 2012: “Effectiveness of influenza vaccine in pregnant women” – WHO Influenza SAGE working group meeting, Geneva, Switzerland.
- Jan. 19, 2013: “Effectiveness of influenza vaccine during pregnancy” – WHO Influenza Asian Meeting, Hong Kong, China
- Jan 29, 2013: “Respiratory Syncytial Virus Prevention and Treatment” – PAHO and CDC Respiratory Disease Conference, San Jose, Costa Rica
- Feb. 25, 2013: New Respiratory Syncytial Virus Vaccines. Maternal Immunization Conference, Antalya, Turkey, sponsored by ESPID.
- March 13-14, 2013: Respiratory virus infections in the immunocompromised host; New WHO guidelines for influenza vaccines. Argentina Pediatric Infectious Disease Society/SLIPE, Buenos Aires, Argentina.
- May 16, 2013: “Maternal Immunization,” Invited Faculty and Moderator, 14th Advanced Vaccinology course co-sponsored by Fondation Merieux/NIH/WHO/CDC, Annecy, France
- 

## CONTINUING MEDICAL EDUCATION:

Frequent speaker at accredited CME talks to area health care workers on topics including immunization, care of immunosuppressed patient, respiratory viral diseases, and influenza, and for local news media and institutions regarding seasonal viruses and pandemic influenza.